Make a deatiled note on Urosepsis using latest SSC 2026 guidelines. Make sure to use all other latest evidance based guidelines for urosepsis
Reading File
Finding Sources
Searching PubMed
urosepsis management guidelines
Searching the Web
Surviving Sepsis Campaign 2025 2026 guidelines urosepsis urinary tract infection sepsis management
Reading Web Page
https://www.idsociety.org/practice-guideline/surviving-sepsi…
Reading File
Finding Sources
Searching PubMed
urosepsis antibiotics outcomes treatment
Reading Web Page
https://www.esicm.org/2026-surviving-sepsis-campaing-guideli…
Reading File
Finding Sources
Searching PubMed
urosepsis "septic shock" obstructive drainage management
Reading File
Finding Sources
Searching the Web
EAU guidelines 2025 2026 urosepsis urological infections management recommendations
Searching PubMed
sepsis "surviving sepsis campaign" antibiotics "source control" 2024 2025
Reading Web Page
https://www.guidelinecentral.com/guideline/4543237
Reading File
Reading Article
PMID: 41597508
Reading Article
PMID: 40216650
Reading File
Finding Sources
I now have comprehensive, authoritative data from all major guidelines. Let me compile the detailed note.
UROSEPSIS - Detailed Clinical Note
Incorporating SSC 2026, EAU 2026, IDSA 2025, and Latest Evidence-Based Guidelines
1. DEFINITION AND OVERVIEW
Urosepsis is defined as sepsis arising from a urinary tract infection (UTI) or urological procedure. Using the Sepsis-3 framework (adopted by SSC 2026), it constitutes:
- Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection originating from the urinary tract, demonstrated by an acute SOFA score increase of ≥2 points from baseline.
- Septic Shock: A subset of urosepsis where underlying circulatory, cellular, and metabolic abnormalities are severe enough to substantially increase mortality - defined by vasopressor requirement to maintain MAP ≥65 mmHg AND serum lactate >2 mmol/L (>18 mg/dL) despite adequate volume resuscitation.
- Quick SOFA (qSOFA) - Bedside screening tool (2 of 3 criteria): Respiratory rate ≥22/min + Altered mentation (GCS <15) + Systolic BP ≤100 mmHg.
Urosepsis accounts for approximately 9-31% of all sepsis cases and carries a mortality of 20-40% when complicated by septic shock. It is the most common form of gram-negative sepsis.
2. PATHOPHYSIOLOGY
2.1 Microbial Triggers
Urosepsis typically originates from bacteremia secondary to:
- Complicated UTI (obstruction, instrumentation, anatomical abnormality)
- Pyelonephritis (especially obstructive)
- Prostate infections / acute bacterial prostatitis
- Post-urological procedures (TURP, ureteroscopy, percutaneous nephrolithotomy, prostate biopsy - 1% risk)
2.2 Microbiology
E. coli remains the dominant pathogen (60-95% of community-acquired cases). Other important organisms:
| Pathogen | Notes |
|---|---|
| Escherichia coli | Most common (60-95%); community-acquired |
| Klebsiella pneumoniae | Often reinfection or hospital-acquired; ESBL rates 20-70% (2026 SR, PMID 41597508) |
| Enterococcus faecalis/faecium | Recurrent/complicated UTI |
| Proteus spp. | Associated with struvite calculi; urease-producing |
| Pseudomonas aeruginosa | Hospital-acquired; catheter-related; MDR concern |
| Serratia / Acinetobacter | Healthcare-associated |
| Candida spp. | Fungal UTI; diabetes, catheter, prior broad-spectrum antibiotics |
ESBL and MDR concerns (EAU 2026): ESBL-producing E. coli and Klebsiella are increasing worldwide (20-70% in some centres). Carbapenemase-producing Enterobacteriaceae (CPE) are emerging. Prior antibiotic use, hospitalization, and catheter are key risk factors.
2.3 Pathogenic Cascade
- Bacterial invasion of kidney/urinary tract
- Hematogenous spread / endotoxin (LPS) release
- Pattern recognition via TLR-4 → NF-kB activation → cytokine storm (TNF-α, IL-1β, IL-6)
- Endothelial injury → capillary leak → hypovolemia
- Nitric oxide and prostacyclin-mediated vasodilation → distributive shock
- Coagulopathy (tissue factor activation, DIC)
- Mitochondrial dysfunction, cellular apoptosis
- Multi-organ failure (ARDS, AKI, hepatic dysfunction, encephalopathy)
3. RISK FACTORS AND PREDISPOSING CONDITIONS
Host factors:
- Female sex (uncomplicated UTI), elderly age
- Diabetes mellitus (most common in obstructive AOP)
- Immunocompromise (transplant, HIV, steroids, malignancy)
- Pregnancy
- Neurogenic bladder, functional urinary obstruction
Structural/anatomical:
- Urolithiasis with obstruction (impacted ureteric stone - a urological emergency)
- BPH / bladder outlet obstruction
- Anatomical anomalies (horseshoe kidney, duplex systems)
- Urinary catheter (CAUTI is the most common source of MDR gram-negative bacteremia in ICUs)
Procedural:
- Post-ureteroscopy/PCNL/TURP
- Prostate biopsy (urosepsis in ~1% of cases)
- Indwelling stent
4. CLINICAL MANIFESTATIONS
Presenting features:
- Fever (>38°C) or hypothermia (<36°C) - hypothermia is an ominous sign
- Rigors / chills
- Flank pain, costovertebral angle tenderness
- Dysuria, frequency, urgency (may be absent in obstructive uropathy)
- Hypotension, tachycardia
- Altered mental status (especially in elderly - may be the only presentation)
- Lethargy, confusion, reduced urine output
Warning features suggesting septic shock / severe urosepsis:
- Systolic BP <90 or MAP <65 mmHg
- Lactate >2 mmol/L
- Mottling, prolonged capillary refill
- Oliguria (<0.5 mL/kg/hr for >2 hours)
- Acute confusion or reduced consciousness
- Thrombocytopenia, hypoalbuminemia (predictors of septic shock in obstructive pyelonephritis - PMID 41597508)
Textbook Note: "Patients who present with urosepsis typically have complicated UTI rather than nonobstructive pyelonephritis. Urosepsis can present with or progress to septic shock, which requires life-supporting treatment in addition to antibiotics." - Goldman-Cecil Medicine, 26th Ed.
5. DIAGNOSIS
5.1 Clinical Diagnosis Frameworks
SSC 2026 (new emphasis): Clinicians must rapidly assess likelihood of infectious vs. noninfectious causes of acute illness. For possible sepsis without shock, perform rapid evaluation before committing to antibiotics. For probable/definite sepsis, treat urgently.
Sepsis-3 / SOFA score: Organ dysfunction confirmed by SOFA ≥2 increase across:
| System | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
| Respiratory PaO2/FiO2 | ≥400 | <400 | <300 | <200 | <100 |
| Coagulation (platelets ×10³/μL) | ≥150 | <150 | <100 | <50 | <20 |
| Liver (bilirubin mg/dL) | <1.2 | 1.2-1.9 | 2.0-5.9 | 6.0-11.9 | >12 |
| Cardiovascular | MAP ≥70 | MAP <70 | Dopamine <5 or dobutamine | Dopa 5.1-15 or epi/norepi ≤0.1 | Dopa >15 or epi/norepi >0.1 |
| CNS (GCS) | 15 | 13-14 | 10-12 | 6-9 | <6 |
| Renal (creat mg/dL) | <1.2 | 1.2-1.9 | 2.0-3.4 | 3.5-4.9 | >5 |
5.2 Laboratory Investigations
Mandatory:
- Urine culture + microscopy - obtain before antibiotics; midstream or catheter specimen; pyuria + bacteriuria support diagnosis
- Blood cultures x2 (from different sites, before antibiotics) - SSC 2026 recommends obtaining cultures before antibiotics but not delaying therapy >45 minutes for culture collection
- Serum lactate - ≥2 mmol/L = hypoperfusion marker; ≥4 mmol/L = high-risk; re-check at 2-4 hours if initially elevated
- FBC: WBC >12,000 or <4,000/mm³; thrombocytopenia is a predictor of shock
- CRP, Procalcitonin (PCT): PCT >1.12 µg/L is a predictor of septic shock in obstructive AOP (PMID 41597508); PCT also guides de-escalation (SSC 2026 - see treatment section)
- Renal function, electrolytes, BUN, creatinine - baseline AKI assessment
- LFTs, bilirubin - hepatic dysfunction assessment (SOFA)
- Coagulation screen (INR, APTT, platelets, D-dimer) - DIC evaluation
- ABG - metabolic acidosis (lactate), oxygenation
- Presepsin - emerging biomarker; elevated in AOP; alongside NLR ≥8.7 predicts shock (PMID 41597508)
Additional:
- Gram stain of urine - rapid identification
- Blood glucose (hyperglycemia common; target <180 mg/dL per SSC 2026)
- Serum albumin (hypoalbuminemia = predictor of septic shock)
- Troponin / BNP if cardiac involvement suspected
SSC 2026 on Procalcitonin (new statement): For initiating antibiotics: suggest using clinical evaluation alone over PCT + clinical evaluation to decide whether to start antimicrobials (conditional recommendation, very low certainty). For discontinuing antibiotics: suggest using PCT AND clinical evaluation over clinical evaluation alone (conditional recommendation, low certainty).
5.3 Imaging
EAU 2026 + Systematic Review (PMID 41597508):
| Modality | Role | Evidence |
|---|---|---|
| Ultrasound (US) | First-line; rapid; detects hydronephrosis, abscess, calculi, obstruction; guides drainage | Bedside availability, no radiation |
| CT scan (non-contrast or contrast) | Gold standard; 71-100% sensitivity for obstructive complications, abscess, gas (emphysematous pyelonephritis); superior to US | Confirms diagnosis, guides intervention |
| MRI | Comparable diagnostic accuracy to CT in selected cases; avoids radiation; use in pregnancy | Selected cases |
| KUB X-ray | Limited value; may show calculi | Low sensitivity |
| CEUS / Doppler US | Assess renal perfusion | Adjunct |
CT of abdomen/pelvis should be performed urgently in all patients with urosepsis to identify obstructing calculi, perinephric abscess, emphysematous pyelonephritis, or other surgically correctable pathology.
6. MANAGEMENT
6.1 Time-Critical Bundle Approach (SSC 2026)
The SSC 2026 emphasizes a bundle approach with time-specific targets:
Hour-1 Bundle (SSC 2026 - confirmed from 2021 update):
- Measure lactate; re-measure if >2 mmol/L
- Obtain blood cultures before antibiotic administration
- Administer broad-spectrum antibiotics
- Begin 30 mL/kg crystalloid IV for hypotension or lactate ≥4 mmol/L
- Apply vasopressors if patient is hypotensive during/after fluid resuscitation to maintain MAP ≥65 mmHg
6.2 Resuscitation (SSC 2026)
Fluid Therapy
- Initial fluid resuscitation: SSC 2026 suggests at least 30 mL/kg IV crystalloid within first 3 hours for sepsis-induced hypoperfusion or septic shock (conditional, low certainty)
- Weight-based calculation on actual body weight; use adjusted/ideal body weight if BMI >30 kg/m²
- Perform frequent ongoing reassessment - avoid over- and under-resuscitation
- Fluid choice: Balanced crystalloids (Ringer's lactate, Plasmalyte) over normal saline (NS) - NS associated with hyperchloremic acidosis; albumin can be used if substantial crystalloid volumes required
- Fluid removal: New SSC 2026 statement - suggest active fluid removal (i.e., diuresis-guided de-resuscitation) once patient is hemodynamically stable
Vasopressors
- First-line: Norepinephrine (noradrenaline) - start at 3-5 µg/min, titrate to MAP target
- MAP target (SSC 2026 - updated):
- Standard target: MAP ≥65 mmHg (strong recommendation)
- New 2026 statement: For older adults (>75 years), a lower MAP target (e.g., 60-65 mmHg) is acceptable (conditional recommendation) - reflecting evidence that higher targets may not improve outcomes in elderly
- Vasopressin: Add as second agent at 0.03 units/min if norepinephrine dose escalating (helps reduce norepinephrine requirements)
- Epinephrine: Third-line agent
- Dopamine: Not recommended as vasopressor in septic shock (increased arrhythmia risk); may be used for bradycardia
- Angiotensin II: Conditional recommendation - may be used as vasopressor in refractory septic shock
- Phenylephrine: Avoid except when norepinephrine causes arrhythmias
Oxygen and Ventilation
- Supplemental oxygen to maintain SpO₂ ≥94%
- ARDS protocol if needed: low tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O, PEEP strategies
6.3 Antimicrobial Therapy (SSC 2026 + IDSA 2025 + EAU 2026)
Timing (SSC 2026 - 2026 Updated Statements)
| Scenario | SSC 2026 Recommendation | Strength |
|---|---|---|
| Probable/definite sepsis without shock | Antibiotics immediately, ideally within 1 hour of recognition | STRONG |
| Possible sepsis without shock | Time-limited rapid investigation; if concern persists, antibiotics within 3 hours | Conditional |
| Septic shock (any sepsis with vasopressor need) | Antibiotics immediately, within 1 hour | STRONG |
Antibiotic Selection (IDSA 2025 cUTI Guidelines + EAU 2026)
IDSA 2025 Four-Step Assessment for Empiric Therapy in urosepsis/complicated UTI:
- Step 1: Risk factors for MDR organisms (prior MDR infection, prior antibiotic exposure, recent hospitalization, long-term care facility, urinary catheter, immunocompromise)
- Step 2: Local antibiogram (use if local, recent, and relevant - conditional recommendation, IDSA 2025)
- Step 3: Patient-specific considerations (allergy, contraindications, drug interactions, AKI)
- Step 4: Antibiotic stewardship (narrowest effective spectrum; de-escalate on culture results)
Empiric antibiotic choices for urosepsis (IDSA 2025, EAU 2026, Goldman-Cecil):
| Clinical Scenario | First-line Options | Alternatives |
|---|---|---|
| Community-acquired urosepsis, no MDR risk | 3rd/4th gen cephalosporin (ceftriaxone 1-2g IV q24h; cefotaxime; cefepime) | Piperacillin-tazobactam 4.5g IV q8h |
| Community-acquired, FQ-susceptible | Ciprofloxacin 400mg IV q12h (if local susceptibility >90%) | Levofloxacin 750mg IV q24h |
| ESBL risk (prior ESBL UTI, fluoroquinolone exposure, healthcare contact) | Carbapenem: Meropenem 1g IV q8h; Ertapenem 1g IV q24h (if stable, no P. aeruginosa risk) | Imipenem-cilastatin; Temocillin (where available) |
| MDR / Pseudomonas risk | Anti-pseudomonal carbapenem (Meropenem, Imipenem, Doripenem) | Cefepime; Piperacillin-tazobactam |
| Carbapenem-resistant (CRE/CPE) | Ceftazidime-avibactam; Meropenem-vaborbactam; Imipenem-cilastatin-relebactam | Cefiderocol; Aztreonam-avibactam (for MBL) |
| Complicated UTI with severe symptoms (Goldman-Cecil) | Plazomicin 15mg/kg IV q24h; OR Meropenem 1g IV q8h for 4-5 days, then oral step-down | Piperacillin-tazobactam; Fosfomycin 6g IV q8h |
| Fungal urosepsis (Candida) | Fluconazole 400mg loading then 200mg q24h (if susceptible, stable) | Echinocandin (caspofungin, micafungin) for septic shock/fluconazole-resistant |
Notes on aminoglycosides (new evidence 2025):
A multicenter retrospective study (Rozenblat et al., Ann Intensive Care 2025, PMID 40216650) of 580 urosepsis ICU patients found that adding aminoglycosides to beta-lactam empirical therapy did not significantly improve 30-day mortality (adjusted HR 0.65, p=0.19) and did not worsen renal outcomes. Goldman-Cecil notes aminoglycosides may be considered in areas with high rates of resistance to other agents. Current consensus: aminoglycosides as single-dose combination (synergy dose) may be considered in severe septic shock or high-resistance settings, but routine combination therapy is not mandatory.
EAU 2026 key principle: Guideline-driven empirical therapy with restricted antibiotics and de-escalation reduces mortality by a relative risk reduction of 35% (95% CI 20-46%); de-escalation to narrower spectrum agents specifically shows 56% RRR in mortality (EAU 2026 PDF).
Duration of Therapy (SSC 2026 + IDSA 2025)
- SSC 2026: Suggests shorter over longer duration of antimicrobial therapy for sepsis/septic shock with adequate source control (conditional, very low certainty)
- Typical duration for urosepsis:
- Uncomplicated bacteremic pyelonephritis after source control: 7-14 days total (oral step-down after 24-48h clinical improvement)
- Goldman-Cecil: 5-7 days adequate for ciprofloxacin/levofloxacin in pyelonephritis
- Septic shock / bacteremia with complications: 14 days (individualize)
- IDSA 2025: No universal recommendation for optimal duration - use clinical judgment + PCT guidance
- Step-down to oral therapy when: clinically improved, tolerating PO, sensitive organism confirmed, gastrointestinal absorption intact - typically 24-48 hours (trimethoprim-sulfamethoxazole, cefixime, or ciprofloxacin - NOT nitrofurantoin or fosfomycin for pyelonephritis/sepsis)
De-escalation and Stewardship (SSC 2026)
- Review antibiotic therapy daily for de-escalation opportunity once cultures and sensitivities available
- SSC 2026 (new 2026 statement): Suggest using PCT AND clinical evaluation to decide when to discontinue antimicrobial therapy (conditional, low certainty)
- Narrow to the most specific, narrowest-spectrum agent
- Stop antibiotics if sepsis diagnosis is not confirmed and clinical evaluation is reassuring
6.4 Source Control (SSC 2026 + EAU 2026)
This is the cornerstone of urosepsis management and a key differentiator from other forms of sepsis.
SSC 2026 (Good Practice Statement): Adults with sepsis or septic shock should be rapidly evaluated for specific anatomical diagnoses or sources of infection that require emergent source control.
SSC 2026: Suggests early source control over late source control, ideally within 6 hours of diagnosis of sepsis or septic shock requiring source control (conditional, very low certainty).
EAU 2026 + Systematic Review (PMID 41597508): Source control through double-J stenting or percutaneous drainage significantly improved survival in obstructive AOP.
Source Control Options in Urosepsis
| Cause | Intervention | Timing |
|---|---|---|
| Obstructing ureteric calculus | Ureteric stenting (retrograde DJ stent) OR percutaneous nephrostomy (PCN) | Emergent - within 6 hours of sepsis diagnosis |
| Perinephric / renal abscess | Percutaneous drainage (image-guided); surgical drainage if inaccessible | Urgent |
| Emphysematous pyelonephritis | Percutaneous drainage + aggressive antibiotics; nephrectomy if unresponsive | Emergency |
| Pyonephrosis | PCN decompression | Emergency |
| Infected obstructed renal transplant | PCN or stent | Emergency |
| Prostatic abscess | Transrectal or transperineal drainage | Urgent |
| Acute bacterial prostatitis | Antibiotics +/− drainage if abscess (no incision of non-abscess prostate) | Urgent |
| Infected urinary catheter | Remove/replace catheter | Immediate |
| Infected ureteric stent | Replace/remove stent | Urgent |
| Post-ureteroscopy sepsis | Drain collecting system; nephrostomy if needed | Emergency |
Key Point: Obstruction-related urosepsis (pyonephrosis, obstructed kidney) MUST be decompressed urgently. Antibiotics alone are insufficient. The obstructed, infected collecting system acts as a reservoir that is inaccessible to antibiotics until drained.
6.5 Corticosteroids (SSC 2026)
- Indication: Septic shock that is unresponsive to adequate fluid resuscitation and vasopressors (refractory shock)
- Regimen: IV hydrocortisone 200 mg/day (continuous infusion preferred over bolus dosing)
- SSC 2026 (maintained from 2021): No additional benefit from doses above 200 mg/day (no benefit at 260 mg/day)
- Do NOT use: Vitamin C IV, IV immunoglobulins, blood purification/hemoperfusion with Polymyxin B (maintained SSC 2026 positions)
- Taper steroids when vasopressors no longer required
6.6 Glucose Management (SSC 2026)
- Start insulin therapy when blood glucose ≥180 mg/dL (10 mmol/L) on two consecutive measurements
- Target glucose range: 144-180 mg/dL (8-10 mmol/L) - avoid hypoglycemia
- Use validated insulin protocols; frequent monitoring
6.7 VTE Prophylaxis (SSC 2026)
- LMWH over unfractionated heparin (UFH) for VTE prophylaxis (maintained 2026)
- Mechanical prophylaxis (compression stockings) when pharmacological prophylaxis is contraindicated
6.8 Renal Replacement Therapy (SSC 2026)
- RRT only for accepted renal indications (refractory acidosis, hyperkalemia, uremic complications, fluid overload refractory to diuretics)
- SSC 2026: Do NOT initiate RRT purely on AKI staging without definitive indication
- Bicarbonate therapy: Only if pH ≤7.20 with AKI Stage 2-3 (AKIN 2-3)
6.9 Blood Transfusion (SSC 2026)
- Restrictive transfusion strategy - transfuse when Hgb <7 g/dL (Hct <21%)
- Hgb target 7-9 g/dL; no benefit to higher targets in most patients
- Exception: Active coronary ischemia, significant ongoing hemorrhage
6.10 ICU / Monitoring Considerations
- ICU admission mandatory for septic shock, refractory hypotension, respiratory failure, multi-organ dysfunction, or high-risk patients
- Continuous monitoring: HR, BP (arterial line preferred), SpO2, urine output, CVP/IVC ultrasound
- POCUS (Point-of-Care Ultrasound): SSC 2026 pediatric guidelines include conditional recommendation for POCUS guidance; adult guidelines support bedside echocardiography for hemodynamic assessment
- Goldman-Cecil: Consider pulmonary artery catheter or echocardiogram especially if known cardiovascular disease
7. BIOMARKERS IN UROSEPSIS
| Biomarker | Role | Key Threshold |
|---|---|---|
| Serum Lactate | Hypoperfusion; risk stratification; treatment response | ≥2 mmol/L = hypoperfusion; ≥4 mmol/L = high mortality risk |
| Procalcitonin (PCT) | Bacterial infection; de-escalation guide; septic shock prediction in AOP | >1.12 µg/L = predictor of shock (PMID 41597508); used for de-escalation (SSC 2026) |
| CRP | Inflammation; less specific | Elevation supports infection |
| Presepsin | Early sepsis diagnosis; septic shock prediction in AOP | Elevated in AOP; combined with NLR ≥8.7 predicts shock (PMID 41597508) |
| Neutrophil-to-Lymphocyte Ratio (NLR) | Septic shock predictor in AOP | NLR ≥8.7 (PMID 41597508) |
| Thrombocytopenia | Predictor of septic shock in obstructive AOP | Platelet count fall (PMID 41597508) |
| Albumin | Hypoalbuminemia = predictor of septic shock | Low albumin + AOP = high risk |
8. ANTIBIOTIC STEWARDSHIP IN UROSEPSIS (EAU 2026)
- Empiric therapy: Use restricted choice based on local antibiogram; include only necessary spectrum
- IV-to-oral switch (IVOST): Transition to oral antibiotics within 24-48 hours of clinical stabilization and confirmed susceptibility
- De-escalation: Narrow spectrum as soon as cultures available - associated with 56% RRR in mortality (EAU 2026)
- Therapeutic drug monitoring (TDM): For aminoglycosides, vancomycin, and other agents with narrow therapeutic index
- Bedside consultation: Infectious disease / clinical pharmacist input improves outcomes
- Duration targets: Shortest effective course; PCT-guided discontinuation (SSC 2026)
2026 French Guidelines (PMID 42061511): Reinforce the importance of preoperative urine culture and antimicrobial stewardship in urology to prevent procedure-related urosepsis.
9. SPECIAL POPULATIONS
9.1 Elderly Patients (SSC 2026 - New 2026 Statement)
- Lower MAP target acceptable (60-65 mmHg instead of 65 mmHg) - conditional recommendation
- High risk of atypical presentation (confusion, falls, absence of fever/dysuria)
- Higher MDR organism risk
9.2 Obstructive Urosepsis
- MUST undergo emergency source control (PCN or DJ stenting)
- CT abdomen/pelvis mandatory
- Higher ESBL/MDR rates
- Carbapenem empiric therapy often appropriate
9.3 Post-Urological Procedure Sepsis
- High risk organisms including ESBL producers, Enterococci, Pseudomonas
- Broader empiric coverage required
- Review local ecology/antibiogram
- 2025 EAU guidelines: Intra-high pressure renal pelvis during ureteroscopy increases risk - manage with adequate drainage post-procedure
9.4 Renal Transplant Recipients
- Post-hoc analysis (PMID 40489015, 2025): Antibiotic practices significantly associated with treatment outcomes in kidney transplant recipients with urosepsis - individualized, culture-guided therapy is essential
- Immunosuppression blunts inflammatory response - presentation may be subtle
9.5 Candida Urosepsis
- EAU 2026: New dedicated chapter on fungal UTI
- Fluconazole for susceptible Candida in stable patients
- Echinocandin (caspofungin/micafungin) for septic shock, azole-resistant species, or C. glabrata/krusei
- Remove/replace urinary catheter
- SSC 2026: Antifungal coverage suggested in sepsis with risk factors for invasive fungal infection (conditional recommendation)
10. COMPLICATIONS
| Complication | Notes |
|---|---|
| Septic shock | Vasopressor requirement; mortality 20-40% |
| Acute Kidney Injury (AKI) | 79.2% of ICU urosepsis patients on admission (PMID 40216650); monitor for need for RRT |
| Emphysematous pyelonephritis | Gas-forming infection; CT diagnosis; emergency nephrectomy vs. drainage |
| Pyonephrosis | Obstructed, pus-filled collecting system; emergency decompression |
| Perinephric abscess | CT-guided or surgical drainage |
| DIC | Coagulopathy; FFP, cryoprecipitate, platelets |
| ARDS | Lung-protective ventilation |
| Multi-organ failure | ICU care |
| Renal papillary necrosis | Diabetes + pyelonephritis; avoid NSAIDs |
11. PROGNOSIS
- Mortality without septic shock: 5-10%
- Mortality with septic shock: 20-40%
- Predictors of poor outcome (PMID 41597508 - Systematic Review 2026):
- Thrombocytopenia
- Hypoalbuminemia
- Procalcitonin >1.12 µg/L
- Presepsin elevation
- NLR ≥8.7
- Delay in source control
- ESBL/MDR pathogen
- Multi-organ involvement at presentation
12. POST-SEPSIS CARE (SSC 2026 - NEW 2026 SECTION)
SSC 2026 introduces, for the first time, a structured post-sepsis recovery section with several new Good Practice Statements:
- Primary care clinicians should be competent to support sepsis survivors
- Post-discharge support strategies should be implemented
- Evaluation of physical, cognitive, and emotional sequelae post-sepsis is mandatory
- Medication review at discharge: Conditional recommendation to perform a complete medication review at discharge - avoid polypharmacy from drugs started during acute illness (sedatives, antacids, antipsychotics) that may not be needed after recovery
- Screen for new/worsened functional limitations, PTSD, anxiety, depression, cognitive impairment
13. GUIDELINE SUMMARY TABLE
| Domain | SSC 2026 | EAU 2026 | IDSA 2025 |
|---|---|---|---|
| Definition | Sepsis-3 (SOFA ≥2) | Sepsis-3 framework | Sepsis-3 framework |
| Antibiotics - septic shock | Within 1 hour (Strong) | Immediate | 4-step empiric selection |
| Antibiotics - probable sepsis no shock | Within 1 hour (Strong) | Based on severity | Empiric selection |
| Antibiotics - possible sepsis no shock | Rapid eval; within 3 hours (Conditional) | - | - |
| Fluid resuscitation | ≥30 mL/kg crystalloid in 3h (Conditional) | Aggressive resuscitation | - |
| MAP target | ≥65 mmHg; 60-65 mmHg acceptable in elderly (NEW) | ≥65 mmHg | - |
| First vasopressor | Norepinephrine | Norepinephrine | - |
| Source control | Within 6 hours (Conditional) | Emergency decompression for obstruction | - |
| PCT for de-escalation | Suggest PCT + clinical eval (Conditional) | De-escalation recommended | Tailor to cultures |
| Corticosteroids | Hydrocortisone 200mg/day for refractory shock | - | - |
| Duration | Shorter preferred with adequate source control | Shortest effective course | Individualized |
| De-escalation | Strong emphasis | 56% RRR mortality | Narrow to susceptibilities |
| Post-sepsis care | NEW: structured recovery, medication review | - | - |
REFERENCES
-
Surviving Sepsis Campaign 2026: Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. DOI: 10.1097/CCM.0000000000007075. Published March 23, 2026. (IDSA page)
-
EAU Guidelines on Urological Infections 2026: Bonkat G, Kranz J, Cai T, et al. EAU Guidelines on Urological Infections. European Association of Urology, April 2026. Updated March 2026. (EAU PDF)
-
IDSA 2025 Complicated UTI Guidelines: Infectious Diseases Society of America. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections. (IDSA page)
-
Goldman-Cecil Medicine, 26th Ed. Chapter 263 - Urinary Tract Infections; Chapter 94 - Sepsis and Septic Shock.
-
Harrison's Principles of Internal Medicine, 22nd Ed. (2025) - Sepsis and Septic Shock.
-
Chibu MC et al. (2026). Clinical Characteristics, Microbiological Spectrum, Biomarkers, and Imaging Insights in Acute Pyelonephritis and Its Complicated Forms - A Systematic Review. Medicina (Kaunas). PMID: 41597508.
-
Rozenblat D et al. (2025). Impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study. Ann Intensive Care. PMID: 40216650.
-
Vallee M et al. (2026). Preoperative urine culture in urology: Indications and management - The 2026 French guidelines. Fr J Urol. PMID: 42061511.
-
Krolicki T et al. (2025). Antibiotic practices in kidney transplant recipients with urosepsis are associated with treatment outcomes. Eur J Clin Microbiol Infect Dis. PMID: 40489015.
Note on SSC 2026: The SSC 2026 adult guidelines contain 129 total statements (46 new), developed by a 69-person panel representing 23 countries, published March 23, 2026 in Critical Care Medicine and Intensive Care Medicine, and endorsed by 24 professional societies including ESICM, SCCM, IDSA, and others. The guidelines do not have a urosepsis-specific chapter but all core principles (antibiotics, source control, resuscitation, stewardship) apply directly to urosepsis management.
Create a clinical decision tree PDF for rapid diagnosis and management of urosepsis in ED/ICU settings
Reading File
Running Command
ls -la /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or not found"
Running Command
mkdir -p /home/daytona/workspace/urosepsis-pdf && python3 -c "import reportlab; print('reportlab ok')" && python3 -c "from reportlab.lib import colors; print('colors ok')"
Writing File
~/urosepsis-pdf/build_urosepsis_pdf.py
"""
Urosepsis Clinical Decision Tree PDF
SSC 2026 + EAU 2026 + IDSA 2025 Guidelines
"""
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.units import mm, cm
from reportlab.platypus import (
SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
HRFlowable, KeepTogether, PageBreak
)
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_RIGHT, TA_JUSTIFY
from reportlab.platypus.flowables import Flowable
from reportlab.graphics.shapes import Drawing, Rect, String, Line, Polygon, Arrow
from reportlab.graphics import renderPDF
import reportlab.graphics.shapes as shapes
# ── Colour palette ──────────────────────────────────────────────────────────
C_RED = colors.HexColor("#C0392B")
C_ORANGE = colors.HexColor("#E67E22")
C_YELLOW = colors.HexColor("#F39C12")
C_GREEN = colors.HexColor("#27AE60")
C_BLUE = colors.HexColor("#2980B9")
C_DARK_BLUE = colors.HexColor("#1A5276")
C_TEAL = colors.HexColor("#148F77")
C_PURPLE = colors.HexColor("#7D3C98")
C_GREY_LT = colors.HexColor("#F2F3F4")
C_GREY_MID = colors.HexColor("#BDC3C7")
C_GREY_DK = colors.HexColor("#5D6D7E")
C_WHITE = colors.white
C_BLACK = colors.black
C_NAVY = colors.HexColor("#1B2631")
C_AMBER_LT = colors.HexColor("#FEF9E7")
C_RED_LT = colors.HexColor("#FDEDEC")
C_GREEN_LT = colors.HexColor("#EAFAF1")
C_BLUE_LT = colors.HexColor("#EAF2FF")
C_TEAL_LT = colors.HexColor("#E8F8F5")
W, H = A4 # 210 × 297 mm
# ── Custom Flowable: Decision Box ────────────────────────────────────────────
class DecisionBox(Flowable):
"""Coloured rounded rectangle with title + body text."""
def __init__(self, title, body_lines, bg=C_BLUE_LT, border=C_BLUE,
title_bg=C_BLUE, title_color=C_WHITE,
width=None, min_height=None, font_size=8):
super().__init__()
self.title = title
self.body_lines = body_lines
self.bg = bg
self.border = border
self.title_bg = title_bg
self.title_color = title_color
self.bwidth = width or (W - 4*cm)
self.font_size = font_size
self._min_height = min_height
self.hAlign = 'CENTER'
def wrap(self, availW, availH):
self.bwidth = min(self.bwidth, availW - 4)
line_h = self.font_size * 1.35
title_h = self.font_size * 1.5 + 6
body_h = len(self.body_lines) * line_h + 10
total = max(title_h + body_h, self._min_height or 0)
self._height = total
return (self.bwidth, total)
def draw(self):
c = self.canv
w, h = self.bwidth, self._height
r = 5
line_h = self.font_size * 1.35
title_h = self.font_size * 1.5 + 6
# Background
c.setFillColor(self.bg)
c.setStrokeColor(self.border)
c.setLineWidth(1.2)
c.roundRect(0, 0, w, h, r, fill=1, stroke=1)
# Title bar
c.setFillColor(self.title_bg)
c.roundRect(0, h - title_h, w, title_h, r, fill=1, stroke=0)
c.rect(0, h - title_h, w, title_h/2, fill=1, stroke=0) # square bottom
# Border on top again
c.setFillColor(self.bg)
c.setStrokeColor(self.border)
c.roundRect(0, 0, w, h, r, fill=0, stroke=1)
# Title text
c.setFillColor(self.title_color)
c.setFont("Helvetica-Bold", self.font_size + 0.5)
c.drawCentredString(w/2, h - title_h + 4, self.title)
# Body lines
c.setFillColor(C_BLACK)
c.setFont("Helvetica", self.font_size)
y = h - title_h - line_h
for line in self.body_lines:
bold = line.startswith("**") and line.endswith("**")
if bold:
line = line[2:-2]
c.setFont("Helvetica-Bold", self.font_size)
else:
c.setFont("Helvetica", self.font_size)
c.drawString(8, y, line)
y -= line_h
class ArrowDown(Flowable):
"""Simple downward arrow connector."""
def __init__(self, label="", color=C_GREY_DK, width=60, height=18):
super().__init__()
self._w = width
self._h = height
self.label = label
self.color = color
self.hAlign = 'CENTER'
def wrap(self, availW, availH):
return (self._w, self._h)
def draw(self):
c = self.canv
cx = self._w / 2
c.setStrokeColor(self.color)
c.setFillColor(self.color)
c.setLineWidth(1.5)
# Stem
c.line(cx, self._h, cx, 6)
# Arrowhead
c.setLineWidth(0)
p = c.beginPath()
p.moveTo(cx, 0)
p.lineTo(cx - 5, 8)
p.lineTo(cx + 5, 8)
p.close()
c.drawPath(p, fill=1, stroke=0)
if self.label:
c.setFillColor(self.color)
c.setFont("Helvetica-Bold", 6.5)
c.drawCentredString(cx, 9, self.label)
class TwoWayBranch(Flowable):
"""Horizontal branch: YES left, NO right with arrow down."""
def __init__(self, yes_label="YES", no_label="NO",
yes_color=C_GREEN, no_color=C_RED, width=None, height=30):
super().__init__()
self._w = width or (W - 4*cm)
self._h = height
self.yes_label = yes_label
self.no_label = no_label
self.yes_color = yes_color
self.no_color = no_color
self.hAlign = 'CENTER'
def wrap(self, availW, availH):
self._w = min(self._w, availW - 4)
return (self._w, self._h)
def draw(self):
c = self.canv
w, h = self._w, self._h
cx = w / 2
c.setStrokeColor(C_GREY_DK)
c.setLineWidth(1.5)
# Horizontal line
c.line(cx - w*0.3, h*0.6, cx + w*0.3, h*0.6)
# Vertical stem down from center
c.line(cx, h, cx, h*0.6)
# YES arrow (left)
c.setStrokeColor(self.yes_color)
c.setFillColor(self.yes_color)
c.line(cx - w*0.3, h*0.6, cx - w*0.3, 8)
p = c.beginPath()
p.moveTo(cx - w*0.3, 0)
p.lineTo(cx - w*0.3 - 5, 8)
p.lineTo(cx - w*0.3 + 5, 8)
p.close()
c.drawPath(p, fill=1, stroke=0)
c.setFont("Helvetica-Bold", 7)
c.drawCentredString(cx - w*0.3, h*0.6 + 4, self.yes_label)
# NO arrow (right)
c.setStrokeColor(self.no_color)
c.setFillColor(self.no_color)
c.line(cx + w*0.3, h*0.6, cx + w*0.3, 8)
p = c.beginPath()
p.moveTo(cx + w*0.3, 0)
p.lineTo(cx + w*0.3 - 5, 8)
p.lineTo(cx + w*0.3 + 5, 8)
p.close()
c.drawPath(p, fill=1, stroke=0)
c.setFont("Helvetica-Bold", 7)
c.drawCentredString(cx + w*0.3, h*0.6 + 4, self.no_label)
# ── Styles ────────────────────────────────────────────────────────────────────
def make_styles():
base = getSampleStyleSheet()
styles = {}
styles['title'] = ParagraphStyle(
'title', parent=base['Title'],
fontSize=18, leading=22, textColor=C_WHITE,
fontName='Helvetica-Bold', alignment=TA_CENTER, spaceAfter=2
)
styles['subtitle'] = ParagraphStyle(
'subtitle', parent=base['Normal'],
fontSize=9, leading=12, textColor=C_WHITE,
fontName='Helvetica', alignment=TA_CENTER, spaceAfter=2
)
styles['section'] = ParagraphStyle(
'section', parent=base['Normal'],
fontSize=11, leading=14, textColor=C_WHITE,
fontName='Helvetica-Bold', alignment=TA_LEFT,
spaceBefore=6, spaceAfter=3,
backColor=C_DARK_BLUE, leftIndent=6, rightIndent=6
)
styles['body'] = ParagraphStyle(
'body', parent=base['Normal'],
fontSize=8, leading=11, textColor=C_BLACK,
fontName='Helvetica', alignment=TA_LEFT,
spaceBefore=1, spaceAfter=1
)
styles['body_bold'] = ParagraphStyle(
'body_bold', parent=base['Normal'],
fontSize=8, leading=11, textColor=C_BLACK,
fontName='Helvetica-Bold', alignment=TA_LEFT
)
styles['small'] = ParagraphStyle(
'small', parent=base['Normal'],
fontSize=6.5, leading=9, textColor=C_GREY_DK,
fontName='Helvetica', alignment=TA_LEFT
)
styles['centre'] = ParagraphStyle(
'centre', parent=base['Normal'],
fontSize=8, leading=10, textColor=C_BLACK,
fontName='Helvetica', alignment=TA_CENTER
)
styles['red_bold'] = ParagraphStyle(
'red_bold', parent=base['Normal'],
fontSize=8.5, leading=11, textColor=C_RED,
fontName='Helvetica-Bold', alignment=TA_LEFT
)
styles['green_bold'] = ParagraphStyle(
'green_bold', parent=base['Normal'],
fontSize=8.5, leading=11, textColor=C_GREEN,
fontName='Helvetica-Bold', alignment=TA_LEFT
)
styles['box_label'] = ParagraphStyle(
'box_label', parent=base['Normal'],
fontSize=7, leading=9, textColor=C_GREY_DK,
fontName='Helvetica-BoldOblique', alignment=TA_CENTER
)
styles['footer'] = ParagraphStyle(
'footer', parent=base['Normal'],
fontSize=6, leading=8, textColor=C_GREY_DK,
fontName='Helvetica', alignment=TA_CENTER
)
return styles
# ── Helper: coloured cell table ───────────────────────────────────────────────
def ctable(data, col_widths, row_heights=None, style_cmds=None):
t = Table(data, colWidths=col_widths, rowHeights=row_heights)
base_style = [
('FONTNAME', (0,0), (-1,-1), 'Helvetica'),
('FONTSIZE', (0,0), (-1,-1), 7.5),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('ROWBACKGROUNDS', (0,0), (-1,-1), [C_WHITE, C_GREY_LT]),
('GRID', (0,0), (-1,-1), 0.4, C_GREY_MID),
('TOPPADDING', (0,0), (-1,-1), 3),
('BOTTOMPADDING',(0,0), (-1,-1), 3),
('LEFTPADDING', (0,0), (-1,-1), 5),
]
if style_cmds:
base_style.extend(style_cmds)
t.setStyle(TableStyle(base_style))
return t
# ── Header banner ──────────────────────────────────────────────────────────────
class HeaderBanner(Flowable):
def __init__(self, width, height=52):
super().__init__()
self._w = width
self._h = height
def wrap(self, availW, availH):
return (self._w, self._h)
def draw(self):
c = self.canv
w, h = self._w, self._h
# Gradient-like effect: dark navy → dark blue
c.setFillColor(C_NAVY)
c.rect(0, 0, w, h, fill=1, stroke=0)
c.setFillColor(C_DARK_BLUE)
c.rect(0, 0, w*0.5, h, fill=1, stroke=0)
# Red accent bar
c.setFillColor(C_RED)
c.rect(0, h-4, w, 4, fill=1, stroke=0)
# Title
c.setFillColor(C_WHITE)
c.setFont("Helvetica-Bold", 17)
c.drawString(14, h-24, "UROSEPSIS Clinical Decision Tree")
# Subtitle
c.setFont("Helvetica", 8)
c.setFillColor(C_GREY_MID)
c.drawString(14, h-36, "Rapid Diagnosis & Management | ED / ICU Setting")
# Guidelines badge
c.setFillColor(C_RED)
c.roundRect(w-168, h-38, 158, 32, 5, fill=1, stroke=0)
c.setFillColor(C_WHITE)
c.setFont("Helvetica-Bold", 7)
c.drawCentredString(w-89, h-22, "SSC 2026 | EAU 2026 | IDSA 2025")
c.setFont("Helvetica", 6.5)
c.drawCentredString(w-89, h-33, "Published: March 2026 / April 2026")
# Bottom strip
c.setFillColor(C_ORANGE)
c.rect(0, 0, w, 3, fill=1, stroke=0)
# ═══════════════════════════════════════════════════════════════════════════════
# MAIN BUILD
# ═══════════════════════════════════════════════════════════════════════════════
def build_pdf(out_path):
doc = SimpleDocTemplate(
out_path, pagesize=A4,
leftMargin=1.4*cm, rightMargin=1.4*cm,
topMargin=1.2*cm, bottomMargin=1.2*cm
)
S = make_styles()
story = []
full_w = W - 2.8*cm
half_w = (full_w - 0.4*cm) / 2
third_w = (full_w - 0.8*cm) / 3
# ── PAGE 1 ────────────────────────────────────────────────────────────────
story.append(HeaderBanner(full_w))
story.append(Spacer(1, 5))
# ─ STEP 1: Suspicion ──────────────────────────────────────────────────────
story.append(DecisionBox(
"STEP 1 — SUSPECT UROSEPSIS",
[
"**Patient presents with ANY combination of UTI symptoms + systemic features:**",
" • Fever (>38°C) or Hypothermia (<36°C) | Rigors / Chills",
" • Dysuria, Frequency, Urgency, Haematuria, Flank/CVA Tenderness",
" • Hypotension (SBP <90 or MAP <65) | Tachycardia (HR >90)",
" • Altered Mentation / Confusion | Tachypnoea (RR >22) | Oliguria",
" • Recent urological procedure / instrumentation | Indwelling urinary catheter",
"",
" HIGH-RISK FLAGS: Obstruction (stone, BPH) • Elderly • Diabetes • Immunocompromised",
" • Renal transplant • Post-PCNL / Ureteroscopy / TURP / Prostate biopsy",
],
bg=C_BLUE_LT, border=C_DARK_BLUE, title_bg=C_DARK_BLUE, font_size=8
))
story.append(ArrowDown(color=C_DARK_BLUE, height=16))
# ─ STEP 2: qSOFA ──────────────────────────────────────────────────────────
story.append(DecisionBox(
"STEP 2 — RAPID SCREENING | qSOFA (Sepsis-3 / SSC 2026)",
[
"Score 1 point each: (≥2 = HIGH suspicion for sepsis → proceed to full SOFA)",
" [ ] Respiratory Rate ≥ 22 / min",
" [ ] Altered Mentation (GCS < 15)",
" [ ] Systolic BP ≤ 100 mmHg",
],
bg=C_AMBER_LT, border=C_YELLOW, title_bg=C_YELLOW,
title_color=C_NAVY, font_size=8.5
))
story.append(ArrowDown(color=C_YELLOW, height=16))
# ─ STEP 3: Workup ─────────────────────────────────────────────────────────
# Two columns: Labs | Imaging
lab_box = DecisionBox(
"STEP 3A — IMMEDIATE INVESTIGATIONS",
[
"**Bloods (STAT):**",
" • Blood cultures ×2 (before antibiotics)",
" • Serum lactate (arterial/venous)",
" • FBC, CRP, Procalcitonin (PCT)",
" • U&E, Creatinine, eGFR",
" • LFTs, Bilirubin",
" • Coagulation (INR, APTT, Platelets, D-dimer)",
" • ABG | Blood glucose | Serum albumin",
" • Presepsin, NLR (if available)",
"",
"**Urine:**",
" • Midstream / catheter specimen: M/C/S + microscopy",
" • Gram stain (rapid)",
],
bg=C_BLUE_LT, border=C_BLUE, title_bg=C_BLUE,
width=half_w, font_size=7.5
)
img_box = DecisionBox(
"STEP 3B — IMAGING (URGENT)",
[
"**1st: Bedside Ultrasound (POCUS)**",
" Hydronephrosis • Calculi • Abscess • Pyonephrosis",
" Bladder volume • IVC collapsibility",
"",
"**2nd: CT Abdomen/Pelvis (urgent)**",
" Gold standard — 71-100% sensitivity",
" (Non-contrast + contrast if renal function allows)",
" → Obstructing stone • Perinephric abscess",
" → Emphysematous pyelonephritis • Pyonephrosis",
"",
"MRI: Pregnancy or contrast contraindicated",
"ECHO: If haemodynamic instability persists",
],
bg=C_TEAL_LT, border=C_TEAL, title_bg=C_TEAL,
width=half_w, font_size=7.5
)
story.append(Table(
[[lab_box, img_box]],
colWidths=[half_w, half_w],
style=TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 0),
('RIGHTPADDING', (0,0), (-1,-1), 0),
('TOPPADDING', (0,0), (-1,-1), 0),
('BOTTOMPADDING', (0,0), (-1,-1), 0),
('COLPADDING', (0,0), (-1,-1), 2),
])
))
story.append(ArrowDown(color=C_TEAL, height=16))
# ─ STEP 4: Diagnosis / Severity ───────────────────────────────────────────
story.append(DecisionBox(
"STEP 4 — CONFIRM DIAGNOSIS & CLASSIFY SEVERITY (Sepsis-3 | SSC 2026)",
[
"**SOFA score: acute increase ≥ 2 points from baseline = SEPSIS**",
" Organ systems scored: Respiratory (PaO₂/FiO₂) | Coagulation (Platelets) | Liver (Bilirubin)",
" Cardiovascular (MAP / vasopressor) | CNS (GCS) | Renal (Creatinine / Urine output)",
],
bg=C_GREY_LT, border=C_GREY_DK, title_bg=C_GREY_DK,
title_color=C_WHITE, font_size=8
))
story.append(Spacer(1, 4))
# Three severity tiers
tier1 = DecisionBox(
"POSSIBLE SEPSIS",
[
"qSOFA < 2",
"Possible infectious source",
"No shock features",
"",
"→ Rapid evaluation",
"→ If concern persists:",
" Antibiotics within 3 hrs",
" (SSC 2026 Conditional)",
],
bg=C_GREEN_LT, border=C_GREEN, title_bg=C_GREEN,
width=third_w, font_size=7.5
)
tier2 = DecisionBox(
"SEPSIS (No Shock)",
[
"SOFA ≥ 2",
"No vasopressor needed",
"Lactate < 2 mmol/L",
"",
"→ Antibiotics within 1 hr",
" (SSC 2026 STRONG)",
"→ IV fluids",
"→ Source control",
],
bg=C_AMBER_LT, border=C_ORANGE, title_bg=C_ORANGE,
title_color=C_WHITE, width=third_w, font_size=7.5
)
tier3 = DecisionBox(
"SEPTIC SHOCK",
[
"Vasopressor needed to",
"maintain MAP ≥ 65 mmHg",
"AND Lactate > 2 mmol/L",
"despite fluid resus.",
"",
"→ Antibiotics NOW (<1hr)",
"→ ICU admission",
"→ Emergency source control",
],
bg=C_RED_LT, border=C_RED, title_bg=C_RED,
width=third_w, font_size=7.5
)
story.append(Table(
[[tier1, tier2, tier3]],
colWidths=[third_w, third_w, third_w],
style=TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 0),
('RIGHTPADDING', (0,0), (-1,-1), 0),
('TOPPADDING', (0,0), (-1,-1), 0),
('BOTTOMPADDING', (0,0), (-1,-1), 0),
('COLPADDING', (0,0), (-1,-1), 2),
])
))
# Footer page 1
story.append(Spacer(1, 5))
story.append(HRFlowable(width="100%", thickness=0.5, color=C_GREY_MID))
story.append(Paragraph(
"Page 1 of 3 | SSC 2026 (CCM DOI: 10.1097/CCM.0000000000007075) | EAU Guidelines on Urological Infections April 2026 | IDSA 2025 cUTI Guidelines "
" For educational use — verify against local protocols and current guidelines",
S['footer']
))
story.append(PageBreak())
# ══════════════════════════════════════════════════════════════════════════
# PAGE 2 — MANAGEMENT
# ══════════════════════════════════════════════════════════════════════════
story.append(HeaderBanner(full_w))
story.append(Spacer(1, 5))
story.append(DecisionBox(
"STEP 5 — HOUR-1 BUNDLE (SSC 2026 | Septic Shock / High-Risk Sepsis)",
[
"**1.** Measure serum LACTATE — re-measure at 2-4 h if initial > 2 mmol/L",
"**2.** Obtain BLOOD CULTURES ×2 (before antibiotics — do NOT delay >45 min for cultures)",
"**3.** Administer BROAD-SPECTRUM IV ANTIBIOTICS immediately (≤1 hour from recognition)",
"**4.** Start IV CRYSTALLOID 30 mL/kg if hypotension or lactate ≥ 4 mmol/L (complete within 3 h)",
"**5.** Start VASOPRESSOR if hypotensive during/after fluid resuscitation → TARGET MAP ≥ 65 mmHg",
],
bg=C_RED_LT, border=C_RED, title_bg=C_RED,
title_color=C_WHITE, font_size=8.5
))
story.append(ArrowDown(color=C_GREY_DK, height=14))
# Resuscitation + Antibiotics side by side
resus = DecisionBox(
"STEP 5A — RESUSCITATION (SSC 2026)",
[
"**FLUIDS:**",
" • Balanced crystalloid preferred (Ringer's Lactate / Plasmalyte)",
" • 30 mL/kg in first 3 h (conditional; actual body wt;",
" IBW/adj-wt if BMI >30)",
" • Reassess frequently — avoid over/under-resuscitation",
" • Albumin if large crystalloid volumes needed",
" • Active fluid REMOVAL once stable (de-resuscitation)",
" — NEW SSC 2026 statement",
"",
"**VASOPRESSORS:**",
" 1st: Norepinephrine (start 3–5 µg/min, titrate)",
" 2nd: Add Vasopressin 0.03 u/min (sparing agent)",
" 3rd: Epinephrine if above inadequate",
" Alt: Angiotensin II (refractory shock)",
" Avoid: Dopamine (arrhythmias)",
"",
"**MAP TARGETS (SSC 2026 — UPDATED):**",
" Standard: MAP ≥ 65 mmHg (STRONG)",
" Elderly (>75y): 60–65 mmHg acceptable",
" (Conditional — new 2026 recommendation)",
"",
"**OXYGEN:** SpO₂ ≥ 94%",
"**VENTILATION (if needed):** TV 6 mL/kg IBW",
],
bg=C_BLUE_LT, border=C_BLUE, title_bg=C_BLUE,
width=half_w, font_size=7.5
)
abx = DecisionBox(
"STEP 5B — ANTIBIOTICS (IDSA 2025 / EAU 2026 / SSC 2026)",
[
"**4-STEP IDSA 2025 EMPIRIC SELECTION:**",
" Step 1: MDR risk? (prior MDR, recent abx, hospital,",
" catheter, immunocomp., LTCF)",
" Step 2: Local antibiogram (if available & relevant)",
" Step 3: Patient factors (allergy, AKI, drug interactions)",
" Step 4: Stewardship (narrowest effective spectrum)",
"",
"**EMPIRIC REGIMENS:**",
" Community-acquired, no MDR risk:",
" Ceftriaxone 1–2g IV q24h OR",
" Piperacillin-tazobactam 4.5g IV q8h",
" FQ-susceptible (susceptibility >90% local):",
" Ciprofloxacin 400mg IV q12h",
" ESBL risk (prior ESBL / FQ exposure):",
" Ertapenem 1g IV q24h (no Pseudo risk) OR",
" Meropenem 1g IV q8h",
" MDR / Pseudomonas risk:",
" Meropenem / Imipenem / Piperacillin-TZB",
" CRE / CPE:",
" Ceftazidime-avibactam OR Meropenem-vaborbactam",
" Candida sepsis:",
" Fluconazole 400mg load → 200mg q24h (stable)",
" Caspofungin (shock / resistant species)",
"",
"**TIMING (SSC 2026):**",
" Septic shock / definite sepsis: ≤ 1 HOUR (STRONG)",
" Possible sepsis, no shock: ≤ 3 HOURS (Conditional)",
],
bg=C_TEAL_LT, border=C_TEAL, title_bg=C_TEAL,
width=half_w, font_size=7.5
)
story.append(Table(
[[resus, abx]],
colWidths=[half_w, half_w],
style=TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 0),
('RIGHTPADDING', (0,0), (-1,-1), 0),
('TOPPADDING', (0,0), (-1,-1), 0),
('BOTTOMPADDING', (0,0), (-1,-1), 0),
('COLPADDING', (0,0), (-1,-1), 2),
])
))
story.append(ArrowDown(color=C_GREY_DK, height=14))
# Source Control
story.append(DecisionBox(
"STEP 6 — SOURCE CONTROL (SSC 2026 Good Practice + EAU 2026) — CORNERSTONE OF UROSEPSIS MANAGEMENT",
[
"**SSC 2026:** Rapidly evaluate for specific anatomical source requiring emergent source control.",
"**Ideally within 6 hours** of sepsis/septic shock diagnosis (Conditional recommendation, very low certainty)",
"**EAU 2026 SR:** Double-J stenting or PCN for obstructive AOP significantly improves survival.",
"",
"**OBSTRUCTION (most common & critical):** Ureteric stone, BPH, stricture, tumour",
" → Retrograde DJ stent (ureterorenoscopy) OR Percutaneous Nephrostomy (PCN) — EMERGENCY",
" → Antibiotics alone are INSUFFICIENT for obstructed, infected kidney",
"",
"**Perinephric / Renal Abscess:** Image-guided percutaneous drainage ± surgical drainage",
"**Emphysematous Pyelonephritis:** PCN + aggressive antibiotics → nephrectomy if no response",
"**Pyonephrosis:** Emergency PCN decompression",
"**Prostatic Abscess:** Transrectal or transperineal drainage",
"**Infected Catheter / Stent:** Remove / replace IMMEDIATELY",
"**Post-procedural sepsis:** Drain collecting system; nephrostomy if needed",
],
bg=colors.HexColor("#FDF2E9"), border=C_ORANGE, title_bg=C_ORANGE,
title_color=C_WHITE, font_size=7.8
))
story.append(Spacer(1, 5))
story.append(HRFlowable(width="100%", thickness=0.5, color=C_GREY_MID))
story.append(Paragraph(
"Page 2 of 3 | SSC 2026 (CCM DOI: 10.1097/CCM.0000000000007075) | EAU Guidelines on Urological Infections April 2026 | IDSA 2025 cUTI Guidelines",
S['footer']
))
story.append(PageBreak())
# ══════════════════════════════════════════════════════════════════════════
# PAGE 3 — ESCALATION, ADJUNCTS, DE-ESCALATION, BIOMARKERS, SPECIAL POPS
# ══════════════════════════════════════════════════════════════════════════
story.append(HeaderBanner(full_w))
story.append(Spacer(1, 5))
# Adjuncts + De-escalation
adj = DecisionBox(
"STEP 7 — ADJUNCTIVE THERAPIES (SSC 2026)",
[
"**CORTICOSTEROIDS:**",
" Indication: Refractory septic shock (vasopressor-unresponsive despite adequate fluids)",
" Regimen: IV Hydrocortisone 200 mg/day (continuous infusion preferred over bolus)",
" No benefit above 200–260 mg/day. Taper when vasopressors no longer needed.",
" Do NOT use: Vitamin C IV | IV Immunoglobulins | Polymyxin B hemoperfusion",
"",
"**GLUCOSE CONTROL:**",
" Start insulin when glucose ≥ 180 mg/dL (×2 consecutive readings)",
" Target: 144–180 mg/dL | Avoid hypoglycaemia | Use validated protocol",
"",
"**VTE PROPHYLAXIS:**",
" LMWH > UFH (SSC 2026) + Mechanical compression if pharmacological contraindicated",
"",
"**RRT (Renal Replacement Therapy):**",
" Only for definite renal indications — NOT purely on AKI stage",
" Bicarbonate: Only if pH ≤ 7.20 with AKI Stage 2–3",
"",
"**BLOOD TRANSFUSION:**",
" Restrictive strategy: Transfuse when Hgb < 7 g/dL | Target 7–9 g/dL",
],
bg=colors.HexColor("#F9F0FF"), border=C_PURPLE, title_bg=C_PURPLE,
width=half_w, font_size=7.5
)
deesc = DecisionBox(
"STEP 8 — DE-ESCALATION & STEWARDSHIP (SSC 2026 + EAU 2026)",
[
"**PCT-GUIDED DE-ESCALATION (SSC 2026 — NEW 2026):**",
" Use PCT + clinical evaluation to decide when to",
" DISCONTINUE antibiotics (Conditional, low certainty)",
" (PCT alone is NOT used to START antibiotics)",
"",
"**EAU 2026 EVIDENCE:**",
" Guideline-driven empiric therapy + de-escalation",
" → 35% RRR in mortality (95% CI 20–46%)",
" Narrowing to specific agent → 56% RRR mortality",
"",
"**DAILY REVIEW:**",
" • Are cultures back? → Narrow spectrum ASAP",
" • IV-to-oral step-down at 24–48 h if:",
" Clinical improvement + tolerating PO +",
" Susceptible organism + GI absorption intact",
" • Oral options: Co-trimoxazole, Cefixime, Cipro",
" (NOT nitrofurantoin / fosfomycin for pyelonephritis)",
"",
"**DURATION:**",
" Uncomplicated bacteraemic pyelonephritis: 7–14 days",
" FQ (pyelonephritis): 5–7 days adequate",
" Septic shock + complications: 14 days (individualise)",
" Prefer SHORTER over longer (SSC 2026 Conditional)",
],
bg=C_GREEN_LT, border=C_GREEN, title_bg=C_GREEN,
width=half_w, font_size=7.5
)
story.append(Table(
[[adj, deesc]],
colWidths=[half_w, half_w],
style=TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 0),
('RIGHTPADDING', (0,0), (-1,-1), 0),
('TOPPADDING', (0,0), (-1,-1), 0),
('BOTTOMPADDING', (0,0), (-1,-1), 0),
('COLPADDING', (0,0), (-1,-1), 2),
])
))
story.append(Spacer(1, 4))
# Biomarkers table + Special populations
bio_data = [
[Paragraph("<b>Biomarker</b>", S['body_bold']),
Paragraph("<b>Role</b>", S['body_bold']),
Paragraph("<b>Key Threshold</b>", S['body_bold'])],
["Serum Lactate", "Hypoperfusion | Risk stratification | Treatment response",
"≥2 mmol/L = hypoperfusion; ≥4 mmol/L = high mortality"],
["Procalcitonin (PCT)", "Bacterial infection | De-escalation guide | Shock predictor",
">1.12 µg/L = predictor of septic shock in obstructive AOP"],
["Presepsin", "Early sepsis diagnosis | Septic shock prediction in AOP",
"Elevated + NLR ≥8.7 = high shock risk"],
["NLR (Neutrophil:Lymphocyte)", "Septic shock predictor in obstructive pyelonephritis",
"NLR ≥ 8.7"],
["Platelets / Albumin", "Septic shock predictors in AOP",
"Thrombocytopenia + hypoalbuminaemia = high risk"],
["CRP", "Inflammation marker (less specific)", "Trend >than absolute value"],
]
bio_t = ctable(
bio_data,
col_widths=[full_w*0.22, full_w*0.5, full_w*0.28],
style_cmds=[
('BACKGROUND', (0,0), (-1,0), C_DARK_BLUE),
('TEXTCOLOR', (0,0), (-1,0), C_WHITE),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [C_WHITE, C_GREY_LT]),
('FONTSIZE', (0,0), (-1,-1), 7),
]
)
sp_data = [
[Paragraph("<b>Population</b>", S['body_bold']),
Paragraph("<b>Key Considerations</b>", S['body_bold'])],
["Elderly (>75y)", "Lower MAP target 60–65 mmHg (SSC 2026 new). Atypical presentation (confusion only). Higher MDR risk."],
["Obstructive uropathy", "Emergency decompression MANDATORY (PCN/DJ stent). Carbapenems often needed. Abx alone insufficient."],
["Post-urological procedure", "Broader empiric coverage. ESBL, Enterococcus, Pseudomonas risk. Review local ecology."],
["Renal transplant", "Immunosuppression blunts signs. Culture-guided Rx essential. (PMID 40489015, 2025)"],
["Diabetes / Immunocomp.", "Higher risk emphysematous PN, fungal sepsis. Consider antifungal if risk factors present."],
["Candida urosepsis", "Fluconazole if susceptible + stable. Echinocandin if shock or resistant. Remove catheter."],
["Pregnancy", "MRI preferred over CT. Cephalosporins / nitrofurantoin (not 3rd trimester). No FQs."],
]
sp_t = ctable(
sp_data,
col_widths=[full_w*0.22, full_w*0.78],
style_cmds=[
('BACKGROUND', (0,0), (-1,0), C_TEAL),
('TEXTCOLOR', (0,0), (-1,0), C_WHITE),
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [C_WHITE, C_TEAL_LT]),
('FONTSIZE', (0,0), (-1,-1), 7),
]
)
story.append(Paragraph(
"<b>KEY BIOMARKERS IN UROSEPSIS</b>",
ParagraphStyle('bh', parent=S['body_bold'], fontSize=8, textColor=C_DARK_BLUE)
))
story.append(bio_t)
story.append(Spacer(1, 4))
story.append(Paragraph(
"<b>SPECIAL POPULATIONS</b>",
ParagraphStyle('sh', parent=S['body_bold'], fontSize=8, textColor=C_TEAL)
))
story.append(sp_t)
story.append(Spacer(1, 4))
# Post-sepsis + Prognosis
post = DecisionBox(
"STEP 9 — POST-SEPSIS CARE (SSC 2026 — NEW 2026 SECTION)",
[
"First edition to include structured post-sepsis recovery recommendations:",
" • Primary care clinicians must be competent to support sepsis survivors",
" • Implement post-discharge support strategies",
" • Evaluate: Physical sequelae | Cognitive impairment | PTSD / Anxiety / Depression",
" • MEDICATION REVIEW at discharge (Conditional — new 2026):",
" Stop drugs started during acute illness that are no longer needed (sedatives, antacids, antipsychotics)",
],
bg=C_GREEN_LT, border=C_GREEN, title_bg=C_GREEN,
width=half_w, font_size=7.5
)
prog = DecisionBox(
"PROGNOSIS + POOR OUTCOME PREDICTORS (SR 2026, PMID 41597508)",
[
"Mortality without shock: 5–10%",
"Mortality with septic shock: 20–40%",
"",
"**Predictors of poor outcome:**",
" • Thrombocytopenia",
" • Hypoalbuminaemia",
" • PCT > 1.12 µg/L",
" • Presepsin elevation",
" • NLR ≥ 8.7",
" • Delay in source control",
" • ESBL / MDR pathogen (20–70%)",
" • Multi-organ failure at presentation",
" • Elderly + comorbidities",
],
bg=C_RED_LT, border=C_RED, title_bg=C_RED,
width=half_w, font_size=7.5
)
story.append(Table(
[[post, prog]],
colWidths=[half_w, half_w],
style=TableStyle([
('VALIGN', (0,0), (-1,-1), 'TOP'),
('LEFTPADDING', (0,0), (-1,-1), 0),
('RIGHTPADDING', (0,0), (-1,-1), 0),
('TOPPADDING', (0,0), (-1,-1), 0),
('BOTTOMPADDING', (0,0), (-1,-1), 0),
('COLPADDING', (0,0), (-1,-1), 2),
])
))
story.append(Spacer(1, 5))
story.append(HRFlowable(width="100%", thickness=0.5, color=C_GREY_MID))
story.append(Paragraph(
"References: SSC 2026 — Prescott HC et al. Crit Care Med, Mar 2026. DOI: 10.1097/CCM.0000000000007075 | "
"EAU Guidelines on Urological Infections 2026 (Bonkat G et al.) | "
"IDSA 2025 cUTI Guidelines | "
"Chibu MC et al. Medicina 2026, PMID 41597508 | "
"Rozenblat D et al. Ann Intensive Care 2025, PMID 40216650 | "
"Goldman-Cecil Medicine 26E | Harrison's 22E 2025",
S['footer']
))
story.append(Paragraph(
"Page 3 of 3 | This decision tree is for educational purposes. Always verify against your institution's current protocols, local antibiogram, and relevant guidelines.",
S['footer']
))
doc.build(story)
print(f"PDF built: {out_path}")
if __name__ == "__main__":
build_pdf("/home/daytona/workspace/urosepsis-pdf/Urosepsis_Clinical_Decision_Tree.pdf")
Running Command
cd /home/daytona/workspace/urosepsis-pdf && python3 build_urosepsis_pdf.py 2>&1
Editing File
~/urosepsis-pdf/build_urosepsis_pdf.py
Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/urosepsis-pdf/build_urosepsis_pdf.py'
Running Command
cd /home/daytona/workspace/urosepsis-pdf && python3 build_urosepsis_pdf.py 2>&1
Running Command
ls -lh /home/daytona/workspace/urosepsis-pdf/Urosepsis_Clinical_Decision_Tree.pdf
PDF generated successfully at 19 KB. Here it is:
Urosepsis Clinical Decision Tree
PDF Document · PDF
What's in the PDF (3 pages, A4):
Page 1 - Diagnosis Pathway
- Step 1: Suspicion triggers (UTI symptoms + systemic features, high-risk flags)
- Step 2: qSOFA rapid screen (Sepsis-3 / SSC 2026)
- Step 3A: Mandatory investigations (bloods - lactate, cultures, PCT, coags; urine M/C/S)
- Step 3B: Imaging (POCUS first → CT gold standard; MRI/ECHO indications)
- Step 4: SOFA-based severity classification into three colour-coded tiers: Possible Sepsis (green) | Sepsis no shock (amber) | Septic Shock (red) - with antibiotic timing targets for each
Page 2 - Management
- Hour-1 Bundle (SSC 2026) in a red alert box
- Resuscitation: fluids (30 mL/kg balanced crystalloid), vasopressor ladder (norepinephrine → vasopressin → epinephrine), updated MAP targets (65 mmHg standard; 60-65 mmHg for elderly >75y - new SSC 2026), de-resuscitation
- Antibiotics: IDSA 2025 four-step empiric selection with full regimen table (community-acquired → ESBL → MDR/Pseudomonas → CRE/CPE → Candida)
- Source Control: cause-by-cause intervention table with timing (obstruction, abscess, emphysematous PN, pyonephrosis, etc.)
Page 3 - Escalation, Stewardship & Follow-up
- Adjuncts: hydrocortisone 200 mg/day (refractory shock), glucose control, VTE prophylaxis, RRT/bicarbonate criteria, transfusion thresholds
- De-escalation: PCT-guided discontinuation (new SSC 2026), EAU 2026 mortality reduction data, oral step-down guide, duration targets
- Biomarker reference table (lactate, PCT, presepsin, NLR, platelets/albumin)
- Special populations table (elderly, obstructive, post-procedure, transplant, diabetic, Candida, pregnancy)
- Post-sepsis care (new SSC 2026 section) + Prognosis/poor outcome predictors
How to start empirical antibiotics in urosepsis & how to de-escalate as per culture reports? Make a detailed note including choice of antibiotics
Reading File
Finding Sources
Finding Sources
Searching PubMed
urosepsis empirical antibiotic de-escalation culture-guided
Searching the Web
IDSA 2025 complicated UTI urosepsis empirical antibiotics de-escalation culture-guided therapy recommendations
Reading Web Page
https://www.emdocs.net/guideline-update-2025-idsa-management…
Finding Sources
Searching PubMed
urosepsis antibiotic treatment ESBL MDR outcomes
Searching the Web
EAU 2026 urosepsis antibiotic recommendations ESBL carbapenem de-escalation IV oral switch procalcitonin
Reading File
Finding Sources
Finding Sources
Searching PubMed
urinary sepsis antibiotic de-escalation procalcitonin guided stewardship
Reading File
Reading File
Searching PubMed
sepsis antibiotic de-escalation procalcitonin guided duration outcomes
Reading Web Page
https://www.idsociety.org/practice-guideline/complicated-uri…
Finding Sources
Searching PubMed
empirical antibiotic therapy urinary tract infection sepsis outcomes carbapenem cephalosporin
I now have all the data I need. Let me compile the comprehensive, detailed note.
EMPIRICAL ANTIBIOTICS IN UROSEPSIS AND DE-ESCALATION STRATEGY
Based on SSC 2026 | IDSA 2025 cUTI Guidelines | EAU 2026 | Harrison's 22E | Goldman-Cecil 26E
PART 1: WHY ANTIBIOTIC CHOICE MATTERS CRITICALLY IN UROSEPSIS
Urosepsis is a time-critical condition where antibiotic therapy interacts directly with patient survival. Harrison's Principles (22E, 2025) establishes the biological basis:
"In patients with bacterial septic shock, there is an estimated 7-8% increase in mortality for every 1-hour delay in appropriate antibiotic administration following shock recognition."
The EAU 2026 goes further with its stewardship data:
- Guideline-driven empirical therapy (restricted antibiotics + de-escalation + IV-oral switch + TDM + bedside consultation) = 35% relative risk reduction in mortality (95% CI 20-46%)
- De-escalation specifically (narrowing to a targeted agent) = 56% relative risk reduction in mortality (95% CI 34-70%)
This means BOTH starting the right antibiotic early AND de-escalating appropriately are survival interventions - not just stewardship exercises.
PART 2: THE IDSA 2025 FOUR-STEP FRAMEWORK FOR EMPIRICAL ANTIBIOTIC SELECTION
The IDSA 2025 Guidelines for Complicated UTI (Trautner BW et al., published July 17, 2025) provide the most current, granular framework for antibiotic selection in urosepsis. It replaces the 2010 IDSA UTI guidelines and is the first dedicated cUTI guideline from IDSA.
The four steps must be worked through in sequence before prescribing:
STEP 1: ASSESS ILLNESS SEVERITY - Does the patient have sepsis?
This is the most important branching point because it determines the breadth of empirical coverage required.
| Scenario | Classification | Antibiotic Approach |
|---|---|---|
| UTI symptoms only, no systemic signs, haemodynamically stable | cUTI without sepsis | Narrower spectrum - 3rd/4th gen cephalosporin, pip-tazo, FQ |
| UTI + SOFA ≥2 (organ dysfunction), no vasopressors | Sepsis (no shock) | Broader spectrum - carbapenems included; antibiotics within 1 hour |
| UTI + vasopressor needed + lactate >2 mmol/L | Septic shock | Broadest empirical coverage; antibiotics immediately (<1 hour); 90% susceptibility target on antibiogram |
IDSA 2025 Distinction (key clinical point):
- With sepsis: Carbapenems ARE appropriate empirically
- Without sepsis: Prefer cephalosporins/pip-tazo/FQ; avoid carbapenems empirically (preserve carbapenem activity)
- Nitrofurantoin and oral fosfomycin: NOT appropriate for urosepsis - these agents do not achieve adequate levels in renal parenchyma and bloodstream
STEP 2: ASSESS MDR RISK FACTORS
Before selecting an antibiotic, screen for risk factors that increase the probability of a resistant organism:
MDR Risk Factors (IDSA 2025 + EAU 2026):
| Risk Factor | Associated Resistance Pattern |
|---|---|
| Prior UTI or bacteraemia with ESBL-producing organism | ESBL (CTX-M, SHV, TEM) - E. coli, Klebsiella |
| Fluoroquinolone exposure in the past 12 months | Fluoroquinolone resistance |
| Prior 3rd-generation cephalosporin exposure | ESBL / AmpC resistance |
| Recent hospitalisation (past 3 months) | Healthcare-associated MDR GNR |
| Long-term care facility (LTCF) resident | MDR Enterobacterales |
| Indwelling urinary catheter / ureteric stent | MDR organisms, Pseudomonas, ESBL |
| Recurrent UTIs with prior antibiotic courses | ESBL, FQ-resistance |
| Post-urological procedure (PCNL, URS, TURP) | Enterococcus, Pseudomonas, ESBL |
| Travel to ESBL/CRE-endemic region (Asia, South Asia, SE Asia, Middle East) | ESBL, CPE/CRE |
| Immunocompromise (transplant, HIV, steroids) | MDR GNR, Pseudomonas, Candida |
| Diabetes mellitus | ESBL, Candida, emphysematous PN |
| Structural urological abnormality / obstruction | MDR organisms |
| Prior known carbapenem-resistant organism (CPE/CRE) | Carbapenem-resistant Enterobacterales (CRE) |
IDSA 2025 specific recommendations:
- Avoid antibiotics to which the patient has had a previously resistant pathogen isolated from urine (conditional, very low certainty)
- Avoid fluoroquinolones if the patient has received any FQ in the past 12 months (conditional, very low certainty)
STEP 3: ASSESS PATIENT-SPECIFIC FACTORS
Modify the antibiotic choice based on:
| Factor | Consideration |
|---|---|
| Penicillin / beta-lactam allergy | Clarify severity (rash vs anaphylaxis); if severe, use aztreonam (GN coverage) ± vancomycin; or use a carbapenem if cross-reactivity acceptable |
| Renal impairment (AKI/CKD) | Dose-adjust: aminoglycosides (avoid or single dose only); pip-tazo dose adjustment; colistin high risk |
| Pregnancy | Safe: cephalosporins, amoxicillin-clavulanate, aztreonam; Avoid: FQs, aminoglycosides (ototoxicity), tetracyclines, TMP-SMX (3rd trimester) |
| Drug-drug interactions | FQs + antiarrhythmics (QT prolongation); vancomycin + nephrotoxins |
| Hepatic impairment | Dose-adjust metronidazole, chloramphenicol |
| Prior adverse drug events | Review medication history |
STEP 4: CONSULT THE LOCAL ANTIBIOGRAM (in sepsis only)
IDSA 2025 (conditional recommendation, very low certainty):
- Use a local antibiogram to tailor empirical choice only if it is:
- Local (same healthcare facility)
- Recent (previous 12 months)
- Relevant to the patient (community vs hospital-acquired)
- Septic shock: Target an antibiotic where ≥90% of the most relevant organism(s) are susceptible
- Sepsis without shock: Target an antibiotic where ≥80% of the most relevant organism(s) are susceptible
- Without sepsis: IDSA makes NO specific recommendation about antibiogram use (knowledge gap)
PART 3: EMPIRICAL ANTIBIOTIC CHOICES - DETAILED REGIMENS
3.1 Community-Acquired Urosepsis - No MDR Risk Factors
Most likely organisms: E. coli (susceptible), Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus (women)
Sepsis WITHOUT Shock (SOFA ≥2, MAP maintained, no vasopressors):
| Drug | Dose | Route | Interval | Notes |
|---|---|---|---|---|
| Ceftriaxone | 1-2 g | IV | q24h | First choice; excellent UTI/bacteraemia coverage; once daily; de-escalate when sensitivities available |
| Cefotaxime | 1-2 g | IV | q8h | Alternative to ceftriaxone |
| Cefepime | 1-2 g | IV | q8-12h | 4th gen; broader GN/GPC; use if Pseudomonas possible |
| Levofloxacin | 750 mg | IV/PO | q24h | Use ONLY if local FQ susceptibility >80-90% AND no FQ exposure in past 12 months |
| Ciprofloxacin | 400 mg | IV | q12h | Same criteria as levofloxacin; preferred FQ for UTI |
| Piperacillin-tazobactam | 4.5 g | IV | q8h (ext. infusion 4h preferred) | Extended infusion optimises PD/PK; use if Enterococcus or mixed flora suspected |
| TMP-SMX | 1 DS tab (960 mg) | PO | q12h | Oral only; adequate only if local susceptibility >80% |
Harrison's 22E (2025): "In patients in whom Pseudomonas is not considered a likely pathogen, then a third-generation cephalosporin such as ceftriaxone or cefotaxime is recommended for gram-negative bacteria coverage."
Septic SHOCK (vasopressors required, lactate >2 mmol/L):
| Drug | Dose | Route | Interval | Notes |
|---|---|---|---|---|
| Piperacillin-tazobactam | 4.5 g | IV | q6-8h (4h extended infusion) | Broad GN + Gram-positive + anaerobic; preferred when Pseudomonas not excluded |
| Cefepime | 2 g | IV | q8h | Anti-pseudomonal 4th gen cephalosporin |
| Meropenem | 1 g | IV | q8h | Reserve for septic shock + MDR risk; superior PK for bacteraemia |
Note on Extended Infusion: Harrison's 22E: "Optimization of antibiotic delivery, such as prolonged infusion of β-lactam antibiotics after the initial infusion, and optimization of pharmacokinetics/pharmacodynamics should be considered."
3.2 ESBL Risk (Most Important Resistance Pattern in Urosepsis)
When to suspect ESBL: Prior ESBL culture, FQ exposure past 12 months, recurrent UTIs, healthcare contact, LTCF, travel to endemic regions
Organisms: ESBL-producing E. coli, ESBL-producing K. pneumoniae
Mechanism: CTX-M type ESBLs hydrolyse all 3rd-gen cephalosporins and penicillins; beta-lactam/beta-lactamase inhibitor combinations (pip-tazo) may have unreliable activity
Important: Ceftriaxone, cefotaxime, cefuroxime, amoxicillin-clavulanate are ALL unreliable against ESBL producers - do NOT use empirically if ESBL risk is present.
| Drug | Dose | Route | Interval | Coverage | Notes |
|---|---|---|---|---|---|
| Ertapenem | 1 g | IV | q24h | ESBL Enterobacterales | First choice for ESBL urosepsis if NO Pseudomonas risk; once daily; excellent urinary penetration |
| Meropenem | 1 g | IV | q8h | ESBL + Pseudomonas | Preferred for septic shock / ICU / Pseudomonas risk |
| Imipenem-cilastatin | 500 mg | IV | q6h | Broad ESBL + Pseudomonas | Alternative |
| Doripenem | 500 mg | IV | q8h (4h infusion) | ESBL + Pseudomonas | Good PK/PD; 4h infusion |
| Temocillin | 2 g | IV | q8h | ESBL Enterobacterales (not Pseudomonas) | Where available (Europe); selective pressure-sparing; no carbapenem |
EAU 2026 evidence on ESBL: "The increasing prevalence of ESBL-producing pathogens underscores the need for antimicrobial stewardship and individualised therapeutic strategies guided by local resistance data." (SR 2026, PMID 41597508: ESBL rates 20-70% in some centres)
3.3 Pseudomonas aeruginosa Risk
When to suspect Pseudomonas: ICU/hospital-acquired, structural lung/urinary disease, indwelling catheter, prior Pseudomonas isolation, cystic fibrosis, neutropenia, post-PCNL
| Drug | Dose | Route | Interval | Notes |
|---|---|---|---|---|
| Piperacillin-tazobactam | 4.5 g | IV | q6h (4h infusion) | Broad anti-pseudomonal; also covers Enterococcus |
| Cefepime | 2 g | IV | q8h | Anti-pseudomonal 4th gen cephalosporin |
| Meropenem | 1 g | IV | q8h | Anti-pseudomonal; also covers ESBL |
| Imipenem-cilastatin | 500 mg | IV | q6h | Anti-pseudomonal; broader |
| Ceftazidime | 2 g | IV | q8h (3h infusion) | Specific anti-pseudomonal; no ESBL coverage |
| Ciprofloxacin | 400 mg | IV | q12h | If susceptible locally; do NOT use if prior FQ exposure |
| Aztreonam | 2 g | IV | q8h | Monobactam; anti-GN only; useful in beta-lactam allergy (no cross-reactivity with penicillin) |
| Ceftolozane-tazobactam | 1.5 g | IV | q8h | MDR/XDR Pseudomonas; novel BL/BLI |
Harrison's 22E: "If Pseudomonas is likely, then cefepime, piperacillin-tazobactam, or a carbapenem such as imipenem or meropenem is recommended."
"In patients at risk for highly resistant gram-negative infections (e.g., patients with prior known highly resistant infections or colonization), use of two empiric gram-negative antibiotics is recommended."
3.4 Carbapenem-Resistant Enterobacterales (CRE/CPE) - "Last Resort" Scenario
When to suspect CRE: Prior CRE culture, previous carbapenem therapy, prolonged ICU stay, renal transplant, healthcare tourism/endemic travel
Types:
- KPC-producing CRE (Klebsiella pneumoniae carbapenemase) - most common in USA/worldwide
- OXA-48-producing CRE - common in Southern Europe, Middle East
- MBL-producing CRE (NDM, VIM, IMP) - metallo-beta-lactamase; more common in Asia/South Asia
| Drug | Spectrum | Dose | Notes |
|---|---|---|---|
| Ceftazidime-avibactam | KPC, OXA-48, AmpC, Pseudomonas | 2.5 g IV q8h (2h infusion) | Does NOT cover MBLs (NDM, VIM); must use with aztreonam for NDM |
| Meropenem-vaborbactam | KPC, AmpC, ESBL | 4 g IV q8h (3h infusion) | KPC coverage; does NOT cover OXA-48 or MBLs |
| Imipenem-cilastatin-relebactam | KPC, AmpC, ESBL, some OXA | 1.25 g IV q6h | Good option for KPC; also covers Pseudomonas |
| Cefiderocol | MBL (NDM, VIM, IMP), Acinetobacter, Stenotrophomonas, CRE | 2 g IV q8h (3h infusion) | Siderophore cephalosporin; broadest resistance coverage |
| Aztreonam + ceftazidime-avibactam | NDM and MBL-producing CRE | Aztreonam 2g IV q6h + Caz-Avi 2.5g IV q8h | Combination required for MBL; aztreonam not hydrolysed by MBLs |
| Plazomicin | KPC-CRE, ESBL | 15 mg/kg IV q24h | Goldman-Cecil: "IV plazomicin (15 mg/kg once daily)... particularly useful for highly resistant organisms" |
| Colistin / Polymyxin B | Pan-resistant GN (last resort) | Variable; TDM required | Significant nephrotoxicity; use only when no alternatives |
The Washington Manual (2025): "Ceftazidime-avibactam is broadly active against gram-negative bacteria, including some P. aeruginosa that are resistant to other antipseudomonal beta-lactams. This agent is also active against ESBL- and AmpC-producing strains and possesses unique activity against KPC- and OXA-48-producing carbapenem-resistant Enterobacterales (CRE). Ceftazidime-avibactam is NOT active against metallo-beta-lactamase-producing organisms."
IDSA 2025 position: Novel beta-lactam/BLI combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) are NOT recommended as empirical first-line agents unless there is prior confirmed CRE infection. Reserve these agents for definitive therapy once CRE is confirmed.
3.5 Gram-Positive Organisms in Urosepsis
Generally less common in urosepsis, but important in specific settings:
| Organism | Setting | Preferred Antibiotic |
|---|---|---|
| Enterococcus faecalis | Recurrent UTI, structural abnormality, post-TURP, urological instrumentation | Ampicillin 2g IV q4h (if susceptible) OR Piperacillin-tazobactam |
| Enterococcus faecium | Nosocomial, often VRE | Linezolid 600mg IV/PO q12h; Daptomycin 6-8 mg/kg IV q24h |
| MRSA (rare in UTI) | IVDU, hospital-acquired, post-procedure | Vancomycin (target AUC/MIC 400-600); Daptomycin |
| Staphylococcus aureus bacteraemia with UTI | Consider endocarditis workup - may be seeding kidney | Flucloxacillin 2g IV q4h (MSSA); Vancomycin (MRSA) |
| Staphylococcus saprophyticus | Young women, uncomplicated | TMP-SMX, nitrofurantoin, FQ (cystitis; not sepsis) |
Harrison's 22E: "In patients with undifferentiated sepsis with risk factors for MRSA (e.g., frequent health care exposure or hospital-onset sepsis), vancomycin or linezolid administration is recommended."
3.6 Fungal Urosepsis (Candida)
Risk factors: Diabetes, indwelling urinary catheter, prior broad-spectrum antibiotics, ICU stay, immunocompromise, parenteral nutrition, abdominal surgery
EAU 2026: Dedicated new chapter on fungal UTI added (previously absent)
| Scenario | Drug | Dose | Notes |
|---|---|---|---|
| Stable, susceptible Candida (non-glabrata/krusei) | Fluconazole | 800 mg loading, then 400 mg IV/PO q24h (for candidaemia) OR 200 mg q24h (lower UTI) | Excellent urinary penetration; also bladder irrigation option for cystitis |
| Septic shock / fluconazole-resistant / C. glabrata / C. auris | Caspofungin | 70 mg IV loading, then 50 mg q24h | First-line echinocandin for candidaemia/septic shock |
| Alternative echinocandin | Micafungin | 100 mg IV q24h | Equivalent to caspofungin |
| C. krusei (innately resistant to fluconazole) | Voriconazole OR echinocandin | 200-300 mg IV/PO q12h | Note: poor urinary penetration with voriconazole; prefer echinocandin if bladder source |
| Remove indwelling catheter | - | - | Critical source control step |
Harrison's 22E: "In patients at increased risk of fungal infection (e.g., recent abdominal surgery, parenteral nutrition, liver failure, diabetes, colonisation of multiple anatomic sites with Candida spp.), empiric echinocandin administration is recommended."
3.7 Antibiotic Dosing Reference Table (IV Antibiotics for Urosepsis)
Based on IDSA 2025 (Table 2.1), Goldman-Cecil 26E, Harrison's 22E, normal renal function - adjust for AKI/CKD
| Antibiotic | Standard IV Dose | Interval | Infusion Duration | Dose Adjustment in AKI |
|---|---|---|---|---|
| Ceftriaxone | 1-2 g | q24h | 30 min | Not required (biliary excretion) |
| Cefotaxime | 1-2 g | q8h | 30 min | Reduce if eGFR <20 |
| Cefepime | 1-2 g | q8-12h | 30-60 min | Reduce if eGFR <50 |
| Ceftazidime | 2 g | q8h | 30 min-3h | Reduce if eGFR <50 |
| Piperacillin-tazobactam | 4.5 g | q6-8h | 4h extended infusion (preferred) | Reduce if eGFR <20 |
| Meropenem | 1-2 g | q8h | 30 min-3h (extended) | Reduce if eGFR <50 |
| Ertapenem | 1 g | q24h | 30 min-1h | Reduce if eGFR <30 |
| Imipenem-cilastatin | 500 mg | q6h | 30-60 min | Reduce if eGFR <70 |
| Ciprofloxacin | 400 mg | q8-12h | 60 min | Reduce if eGFR <30 |
| Levofloxacin | 500-750 mg | q24h | 60 min | Reduce if eGFR <50 |
| Vancomycin | AUC-guided (25-30 mg/kg loading) | q8-12h | 1-2h | TDM essential; reduce in AKI |
| Gentamicin | 5-7 mg/kg (single-dose synergy) | q24h | 30-60 min | TDM essential; single-dose in AKI |
| Amikacin | 15-20 mg/kg | q24h | 30-60 min | TDM essential |
| Ceftazidime-avibactam | 2.5 g | q8h | 2h | Reduce if eGFR <50 |
| Meropenem-vaborbactam | 4 g (2/2) | q8h | 3h | Reduce if eGFR <50 |
| Imipenem-relebactam | 1.25 g | q6h | 30 min | Reduce if eGFR <90 |
| Cefiderocol | 2 g | q8h | 3h | Reduce if eGFR <60 |
| Plazomicin | 15 mg/kg | q24h | 30 min | TDM; caution in AKI |
| Aztreonam | 2 g | q6-8h | 30 min-3h | Reduce if eGFR <30 |
| Caspofungin | 70 mg loading; 50 mg maintenance | q24h | 1h | No dose adjustment |
| Fluconazole | 800 mg loading; 400-800 mg maint. | q24h | 1h | Reduce by 50% if eGFR <50 |
PART 4: ANTIBIOTIC DE-ESCALATION STRATEGY
De-escalation is not just a stewardship intervention - in urosepsis, it is an active survival strategy. The evidence:
- EAU 2026: De-escalation to a narrower spectrum agent = 56% relative risk reduction in mortality
- SSC 2026: Suggests shorter over longer duration with adequate source control (conditional, very low certainty)
- SSC 2026: Suggests using PCT AND clinical evaluation together to guide discontinuation (conditional, low certainty)
De-escalation has three interconnected components:
- Spectrum narrowing - switching to a more targeted drug based on culture
- IV-to-oral (IVOST) switch - reducing route when clinically appropriate
- Duration optimisation - shortest effective course
4.1 When to De-Escalate: The Culture-Guided Algorithm
Blood and urine cultures collected before antibiotics
↓
Empirical antibiotics started (Hour 1)
↓
Culture results: typically available at:
- Urine culture: 24-48 hours (final sensitivities 48-72h)
- Blood cultures: 12-72 hours (bottles flag positive)
↓
REASSESS at 48-72 hours:
1. What did the culture grow?
2. What is the sensitivity pattern?
3. Is the patient clinically improving?
4. Is there source control?
↓
De-escalate to narrowest effective agent
Goldman-Cecil 26E: "The empiric therapy selected should be reassessed after 48 to 72 hours, by which time the urine culture result should be available, so the response to initial therapy can be modified to an agent to which the organism is susceptible, irrespective of the clinical response."
4.2 Spectrum Narrowing by Culture Result - Definitive Therapy
IDSA 2025 (Conditional recommendation, low certainty): "In patients with confirmed complicated UTI, suggest selecting a definitive effective antibiotic with a targeted spectrum based on results of urine culture (identification and susceptibility) as soon as available, rather than continuing empiric broad-spectrum antibiotics for the complete duration of treatment."
Scenario A: Culture confirms susceptible E. coli or Klebsiella
| Empirical Agent | De-escalate to | Route |
|---|---|---|
| Meropenem / Ertapenem (was started for ESBL risk) | Ceftriaxone 1-2g q24h (if susceptible to 3rd-gen cephalosporins) OR Co-trimoxazole 960mg q12h (if susceptible) | IV then PO step-down |
| Piperacillin-tazobactam | Ceftriaxone (if susceptible) | IV then PO |
| Any IV agent | Oral step-down after 24-48h improvement (see IVOST section) | PO |
Scenario B: Culture confirms ESBL-producing E. coli or Klebsiella
| Culture Result | Definitive Agent | Dose | Notes |
|---|---|---|---|
| ESBL, susceptible to ertapenem | Ertapenem 1g IV q24h → step-down to oral | IV → PO | Once daily; good for step-down |
| ESBL, susceptible to TMP-SMX | Co-trimoxazole 960mg PO q12h | PO (after IV induction) | If susceptible, excellent oral bioavailability |
| ESBL, susceptible to FQ (ciprofloxacin MIC ≤0.25) | Ciprofloxacin 500mg PO q12h | PO step-down | Only if confirmed susceptible; excellent oral bioavailability |
| ESBL, susceptible to fosfomycin | Fosfomycin 3g PO q2-3 days | PO | Only for bladder infections; NOT pyelonephritis/bacteraemia |
| ESBL, multiple resistance | Continue carbapenem; ID consultation | IV | Consider ceftazidime-avibactam if carbapenem resistance co-present |
Scenario C: Enterococcus faecalis (susceptible)
| Result | Definitive Agent | Dose | Notes |
|---|---|---|---|
| Ampicillin-susceptible E. faecalis | Ampicillin 2g IV q4-6h OR Amoxicillin 875mg PO q8h (step-down) | IV → PO | Stop GN coverage if mixed flora cleared |
| VRE (ampicillin-resistant, vancomycin-resistant) | Linezolid 600mg IV/PO q12h OR Daptomycin 6mg/kg IV q24h | IV → PO (linezolid) | ID consultation; long-term VRE management |
Scenario D: Pseudomonas aeruginosa
| Susceptibility | Agent | Dose | Notes |
|---|---|---|---|
| FQ-susceptible | Ciprofloxacin 500-750mg PO q12h | PO | Best oral option for Pseudomonas; excellent bioavailability |
| FQ-resistant, pip-tazo susceptible | Continue piperacillin-tazobactam IV | IV | No oral step-down unless ciprofloxacin-susceptible |
| MDR Pseudomonas | Ceftolozane-tazobactam or Ceftazidime-avibactam | IV | Based on susceptibility testing; ID consultation |
Scenario E: CRE / CPE confirmed
| Mechanism | Definitive Agent | Notes |
|---|---|---|
| KPC (carbapenemase) | Ceftazidime-avibactam 2.5g IV q8h | First choice for KPC-CRE |
| OXA-48 | Ceftazidime-avibactam 2.5g IV q8h | Active against OXA-48 |
| MBL (NDM, VIM, IMP) | Aztreonam 2g IV q6h + Ceftazidime-avibactam 2.5g IV q8h OR Cefiderocol 2g IV q8h | Combination needed; aztreonam not hydrolysed by MBLs but requires BLI protection |
| Unknown mechanism, panresistant | Cefiderocol ± polymyxin; ID consultation | Last resort; TDM |
Scenario F: Candida confirmed
| Species | Definitive Agent | Notes |
|---|---|---|
| C. albicans (susceptible) | Fluconazole 400mg IV/PO q24h | De-escalate from echinocandin if stable and susceptible |
| C. glabrata | Echinocandin (caspofungin/micafungin) throughout | Do NOT de-escalate to fluconazole without susceptibility testing |
| C. krusei | Echinocandin or Voriconazole | Innately fluconazole-resistant |
| C. auris | Echinocandin | Often multidrug-resistant; ID consultation essential |
4.3 NEGATIVE CULTURE - What to Do?
SSC 2026 (new 2026 statement): Use clinical evaluation alone over procalcitonin + clinical evaluation to decide whether to START antimicrobials (conditional, very low certainty). But for stopping antibiotics: use PCT AND clinical evaluation together (conditional, low certainty).
If cultures are negative:
- Reassess: Was the sample taken before antibiotics? Quality adequate? Prior antibiotic suppression?
- Check if diagnosis of sepsis is confirmed - if not, SSC 2026 recommends stopping antibiotics
- Consider non-infectious differentials (PE, autoimmune, crystal arthritis, drug fever)
- Use PCT trajectory:
- PCT falling by >80% from peak = reassuring; consider stopping/narrowing
- PCT persistently elevated = may indicate ongoing infection or undrained source
- If clinical suspicion remains: Continue antibiotics but review daily; repeat cultures; broaden investigation
4.4 IV-to-Oral Antibiotic Switch (IVOST) - IDSA 2025
IDSA 2025 (conditional recommendation, very low certainty): "In patients presenting with complicated UTI with associated Gram-negative bacteraemia treated initially with parenteral therapy who are clinically improving, able to take oral medication, and for whom an effective oral option is available, suggest transitioning to oral antibiotics rather than continuing parenteral therapy for the remaining treatment duration."
Criteria for IVOST (ALL must be met):
| Criterion | Detail |
|---|---|
| Clinical improvement | Fever resolving/resolved; haemodynamically stable; heart rate improving; not on vasopressors |
| Able to take oral medication | Tolerating PO; no vomiting; functioning GI tract; no ileus, obstruction, or malabsorption |
| Effective oral option available | Organism susceptible to an oral agent that achieves adequate tissue levels (see table below) |
| Source control achieved | Obstruction drained; catheter managed; abscess drained if present |
| Bacteraemia improving | Repeat blood cultures negative or clinically resolved |
Timing: Typically 24-48 hours after initiation of IV therapy in pyelonephritis/urosepsis (Goldman-Cecil: "transition to oral treatment is normally possible at 24 to 48 hours if the patient has clinically improved")
Oral Step-Down Agents by Organism Susceptibility (IDSA 2025, Table 1.2):
| Oral Antibiotic | Dose | Suitable For | NOT Suitable For | Notes |
|---|---|---|---|---|
| Ciprofloxacin | 500-750 mg q12h | Pyelonephritis, bacteraemia (GN), Pseudomonas | FQ-resistant organisms; prior FQ exposure | Excellent bioavailability (~70-80%); preferred FQ for UT |
| Levofloxacin | 750 mg q24h | Pyelonephritis, bacteraemia (GN) | FQ-resistant | Once daily; equivalent to cipro |
| Co-trimoxazole (TMP-SMX) | 960 mg (DS) q12h | Pyelonephritis, bacteraemia (if susceptible) | TMP-SMX-resistant organisms; 3rd trimester pregnancy; G6PD deficiency | Must confirm susceptibility; local resistance often >20% |
| Cefixime | 400 mg q24h | Pyelonephritis (if susceptible GN) | Pseudomonas, ESBL, Enterococcus | Oral 3rd-gen cephalosporin; reasonable tissue penetration |
| Amoxicillin | 500-875 mg q8h | Enterococcus faecalis (if susceptible) | ESBL-GN; Pseudomonas; most E. coli (resistant) | Only for confirmed ampicillin-susceptible Enterococcus |
| Amoxicillin-clavulanate | 875/125 mg q12h | Select uncomplicated/mild cUTI (community-acquired) | ESBL producers; sepsis | Less studied; not preferred over FQ/TMP-SMX |
| Fosfomycin | 3 g single dose or 3g q48h | Bladder-only ESBL/MDR infections | Pyelonephritis; bacteraemia; sepsis | Does NOT achieve adequate renal parenchyma levels - NOT for upper tract/blood |
| Nitrofurantoin | 100 mg (macrocrystalline) q12h | Bladder-only uncomplicated infection | Pyelonephritis; bacteraemia; sepsis; eGFR <45 | Same as fosfomycin - inadequate systemic levels |
| Fluconazole | 200-400 mg q24h | Candida UTI/candidaemia (susceptible species) | C. glabrata, C. krusei, C. auris | Check species susceptibility first |
| Linezolid | 600 mg q12h | VRE, MRSA (where oral needed) | GN organisms | IV = PO bioavailability; IV-to-PO switch is seamless |
| Voriconazole | 200 mg q12h | Invasive Aspergillus; C. krusei | Poor urinary penetration; not for isolated UTI | Hepatotoxicity; drug interactions |
Critical reminder (IDSA 2025 + Goldman-Cecil): Nitrofurantoin and oral fosfomycin are NOT suitable oral step-down agents after urosepsis/pyelonephritis - they do not achieve sufficient concentrations in the renal parenchyma or bloodstream to be effective for upper tract or systemic disease, even if the organism appears "susceptible" on MIC testing.
4.5 Duration of Antibiotic Therapy - Evidence-Based Targets
SSC 2026 (conditional, very low certainty): Suggests shorter over longer duration of antimicrobial therapy for sepsis/septic shock with adequate source control.
IDSA 2025 (conditional, low certainty): "In patients presenting with complicated UTI with associated Gram-negative bacteraemia and who are improving clinically on effective therapy, suggest treating with a shorter course (7 days) rather than a longer course (14 days)."
| Clinical Scenario | Total Duration | Evidence Base |
|---|---|---|
| Bacteraemic pyelonephritis, improving, source controlled | 7 days total (IV + oral combined) | IDSA 2025 (conditional, low certainty) |
| Uncomplicated bacteraemia from UTI (non-obstructed) | 7-10 days | IDSA 2025; Goldman-Cecil |
| Pyelonephritis (bacteraemia, treated with FQ) | 5-7 days | Goldman-Cecil 26E; shorter course adequate for FQ |
| Complicated UTI without bacteraemia, source controlled | 7 days | IDSA 2025 (7 vs 14 days, NI shown) |
| Septic shock (multi-organ involvement, bacteraemia) | 14 days (individualise) | Standard of care; review with ID |
| Obstructive urosepsis after decompression | 10-14 days (individualise) | Clinical consensus; EAU |
| Emphysematous pyelonephritis post-drainage | 4-6 weeks (varies by extent) | Case series; ID consultation |
| Prostatic abscess post-drainage | 4-6 weeks | FQ-based; tissue penetration critical |
| Renal abscess post-drainage | 4-6 weeks | IV induction then oral; ID consultation |
| Candidaemia (urinary source) | 14 days after last positive culture | IDSA Candida guidelines |
4.6 PCT-Guided De-Escalation (SSC 2026 - Updated 2026 Statement)
SSC 2026 (conditional, low certainty) - NEW 2026: "Suggest using procalcitonin AND clinical evaluation to decide when to discontinue antimicrobial therapy over clinical evaluation alone."
This reverses a nuanced position from 2021 - PCT guidance is now recommended for STOPPING antibiotics, while PCT is NOT recommended to determine whether to start them.
PCT De-escalation Protocol:
| PCT Finding | Interpretation | Action |
|---|---|---|
| PCT falling >80% from peak value | Strong bacterial infection resolving | Plan antibiotic discontinuation with clinical confirmation |
| PCT <0.5 µg/L (in non-critically ill) | Low probability of ongoing bacterial infection | Can discontinue antibiotics if clinically improving |
| PCT <0.1 µg/L | Bacterial infection very unlikely | Stop antibiotics |
| PCT static or rising despite treatment | Ongoing infection / undrained source / wrong antibiotic | Do NOT de-escalate; re-evaluate source control, resistance, diagnosis |
| PCT elevated but patient clinically improved, cultures positive and treated | Clinical picture overrides; apply antibiogram | Follow culture-guided therapy; use PCT as one data point |
EAU 2026 on stewardship programme elements: "De-escalation, intravenous to oral switch, therapeutic drug monitoring and bedside consultation resulted in 35% RRR in mortality." - The combined bundle matters, not PCT alone.
PART 5: SPECIAL SITUATIONS IN ANTIBIOTIC MANAGEMENT
5.1 Allergy to Penicillin / Beta-Lactams
| Allergy Type | Safe Alternatives |
|---|---|
| Non-severe (rash, GI) | 3rd/4th gen cephalosporins (cross-reactivity <2%); carbapenems (cross-reactivity ~1%); risk usually outweighed by benefit in sepsis |
| Severe (anaphylaxis, urticaria, SJS) | Aztreonam (monobactam - NO cross-reactivity with penicillin) + gentamicin; Aztreonam + ciprofloxacin; Tigecycline (if susceptible); consider allergy de-labelling after recovery |
| Carbapenem allergy | Aztreonam (GN only); FQ if susceptible; avoid pip-tazo (beta-lactam) |
| FQ allergy / contraindication | Aminoglycosides (short course TDM-guided); aztreonam; TMP-SMX if susceptible |
5.2 AKI in Urosepsis (79.2% of ICU urosepsis patients on admission - PMID 40216650)
- Avoid aminoglycosides in established AKI unless no alternative (PMID 40216650: adding aminoglycosides did not significantly improve 30-day mortality, and was not associated with worse renal outcomes in propensity-adjusted analysis, but caution warranted)
- Dose-adjust all renally-eliminated antibiotics using eGFR
- For meropenem in AKI: eGFR 26-50 → 1g q12h; eGFR 10-25 → 500mg q12h
- Monitor vancomycin trough/AUC if used; prefer linezolid for VRE if AKI severe
- Extended infusion of beta-lactams (3-4h) compensates for altered PK/PD in AKI/sepsis
5.3 Optimising Pharmacokinetics/Pharmacodynamics (PK/PD)
Harrison's 22E: "Optimization of antibiotic delivery, such as administering β-lactam antibiotics prior to vancomycin, prolonged infusion of β-lactam antibiotics after the initial infusion, and optimization of PK/PD should be considered in consultation with trained pharmacy and infectious diseases experts."
- Beta-lactams (cephalosporins, carbapenems, pip-tazo): Time-dependent killing - maximise % time above MIC by extending infusion (3-4h infusions) or continuous infusion; particularly important in severe septic shock and raised MIC organisms
- Aminoglycosides: Concentration-dependent killing - once-daily dosing achieves better Cmax/MIC ratio and reduces nephrotoxicity
- Fluoroquinolones: Concentration-dependent - AUC/MIC ratio drives efficacy; once or twice daily dosing adequate
- Vancomycin: AUC-guided dosing (target AUC/MIC 400-600) replacing trough-guided dosing; reduces nephrotoxicity
- Therapeutic Drug Monitoring (TDM): Mandatory for vancomycin, aminoglycosides; recommended for beta-lactams in critically ill (pip-tazo, meropenem) when MIC is elevated
PART 6: ANTIMICROBIAL STEWARDSHIP PRINCIPLES SUMMARY (EAU 2026)
The EAU 2026 bundle that achieves 35% RRR in mortality consists of:
- Restricted empirical choice - Use guidelines, not habit; always consider local antibiogram
- De-escalation - Change to narrower agent as soon as cultures allow (56% RRR mortality)
- IV-to-oral switch - As soon as clinically safe (reduces catheter complications, length of stay, cost)
- Therapeutic Drug Monitoring - For aminoglycosides, vancomycin, and beta-lactams in critically ill
- Bedside consultation - Infectious diseases or clinical pharmacist review improves outcomes
- Avoid unnecessary antibiotics - If cultures negative and diagnosis uncertain, stop antibiotics (SSC 2026)
- PCT-guided cessation - Use PCT + clinical evaluation to decide when to stop (SSC 2026)
PART 7: PRACTICAL DECISION TABLE - ORGANISM-TO-ANTIBIOTIC QUICK REFERENCE
| Organism | Resistance Pattern | Empirical (before cultures) | Definitive (after cultures) | Oral Step-Down |
|---|---|---|---|---|
| E. coli | Susceptible | Ceftriaxone | Ceftriaxone → narrow further | TMP-SMX, Ciprofloxacin, Cefixime |
| E. coli | ESBL | Ertapenem / Meropenem | Ertapenem (if no pseudo risk) | TMP-SMX or Ciprofloxacin (if susceptible) |
| Klebsiella pneumoniae | Susceptible | Ceftriaxone | Ceftriaxone | TMP-SMX, Ciprofloxacin |
| Klebsiella pneumoniae | ESBL | Ertapenem / Meropenem | Ertapenem | Ciprofloxacin / TMP-SMX (if susceptible) |
| Klebsiella pneumoniae | KPC-CRE | Ceftazidime-avibactam | Ceftazidime-avibactam | Limited oral options; ID consultation |
| Klebsiella pneumoniae | NDM-MBL | Aztreonam + Caz-avi / Cefiderocol | Aztreonam + Caz-avi or Cefiderocol | ID consultation |
| Pseudomonas aeruginosa | Susceptible | Pip-tazo / Cefepime / Meropenem | Pip-tazo or Cefepime (narrow from carbapenem) | Ciprofloxacin 750mg q12h |
| Pseudomonas aeruginosa | MDR | Ceftolozane-tazo / Caz-avi | Based on susceptibility | ID consultation |
| Enterococcus faecalis | Ampicillin-susceptible | Pip-tazo | Ampicillin | Amoxicillin |
| Enterococcus faecium | VRE | Linezolid | Linezolid / Daptomycin | Linezolid PO |
| Proteus mirabilis | Susceptible | Ceftriaxone | Ceftriaxone / Amp-sulbactam | TMP-SMX, Ciprofloxacin |
| Candida albicans | FLC-susceptible | Echinocandin (if shock) / FLC (if stable) | Fluconazole (de-escalate from echinocandin if stable) | Fluconazole PO |
| Candida glabrata | FLC-resistant | Echinocandin | Echinocandin | Micafungin PO if available |
REFERENCES
-
SSC 2026: Prescott HC et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. DOI: 10.1097/CCM.0000000000007075. March 23, 2026.
-
IDSA 2025 cUTI Guidelines: Trautner BW, Cortés-Penfield NW, Gupta K et al. 2025 Clinical Practice Guideline by IDSA: Management and Treatment of Complicated Urinary Tract Infections. Clin Infect Dis. Published July 17, 2025.
-
EAU Guidelines on Urological Infections 2026 (Bonkat G, Kranz J et al.). April 2026. Limited update March 2026. [PDF available via EAU website]
-
Harrison's Principles of Internal Medicine, 22nd Ed. (2025, McGraw-Hill) - Chapters on Sepsis & Urinary Tract Infections.
-
Goldman-Cecil Medicine, 26th Ed. - Chapter 263 (Urinary Tract Infections) and Chapter 94 (Sepsis).
-
The Washington Manual of Medical Therapeutics - Novel Gram-Negative Antibiotics vs Resistant Organisms.
-
Chibu MC et al. (2026). Systematic Review: Clinical Characteristics, Microbiological Spectrum, Biomarkers, and Imaging Insights in Acute Pyelonephritis and Its Complicated Forms. Medicina (Kaunas). PMID: 41597508.
-
Rozenblat D et al. (2025). Impact of aminoglycosides on survival in urosepsis. Ann Intensive Care. PMID: 40216650.
This is a shared conversation. Sign in to Orris to start your own chat.